Patent Grant
9668809
Technical Field
The present invention generally relates to systems, assemblies, and methods for treating a bronchial tree, and more particularly, the invention relates to systems, assemblies, and methods for eliciting a desired response.
Description of the Related Art
Pulmonary diseases may cause a wide range of problems that adversely affect performance of the lungs. Pulmonary diseases, such as asthma and chronic obstructive pulmonary disease (“COPD”), may lead to increased airflow resistance in the lungs. Mortality, health-related costs, and the size of the population having adverse effects due to pulmonary diseases are all substantial. These diseases often adversely affect quality of life. Symptoms are varied but often include cough; breathlessness; and wheeze. In COPD, for example, breathlessness may be noticed when performing somewhat strenuous activities, such as running, jogging, brisk walking, etc. As the disease progresses, breathlessness may be noticed when performing non-strenuous activities, such as walking. Over time, symptoms of COPD may occur with less and less effort until they are present all of the time, thereby severely limiting a person's ability to accomplish normal tasks.
Pulmonary diseases are often characterized by airway obstruction associated with blockage of an airway lumen, thickening of an airway wall, alteration of structures within or around the airway wall, or combinations thereof. Airway obstruction can significantly decrease the amount of gas exchanged in the lungs resulting in breathlessness. Blockage of an airway lumen can be caused by excessive intraluminal mucus or edema fluid, or both. Thickening of the airway wall may be attributable to excessive contraction of the airway smooth muscle, airway smooth muscle hypertrophy, mucous glands hypertrophy, inflammation, edema, or combinations thereof. Alteration of structures around the airway, such as destruction of the lung tissue itself, can lead to a loss of radial traction on the airway wall and subsequent narrowing of the airway.
Asthma can be characterized by contraction of airway smooth muscle, smooth muscle hypertrophy, excessive mucus production, mucous gland hypertrophy, and/or inflammation and swelling of airways. These abnormalities are the result of a complex interplay of local inflammatory cytokines (chemicals released locally by immune cells located in or near the airway wall), inhaled irritants (e.g., cold air, smoke, allergens, or other chemicals), systemic hormones (chemicals in the blood such as the anti-inflammatory cortisol and the stimulant epinephrine), local nervous system input (nerve cells contained completely within the airway wall that can produce local reflex stimulation of smooth muscle cells and mucous glands), and the central nervous system input (nervous system signals from the brain to smooth muscle cells and mucous glands carried through the vagus nerve). These conditions often cause widespread temporary tissue alterations and initially reversible airflow obstruction that may ultimately lead to permanent tissue alteration and permanent airflow obstruction that make it difficult for the asthma sufferer to breathe. Asthma can further include acute episodes or attacks of additional airway narrowing via contraction of hyper-responsive airway smooth muscle that significantly increases airflow resistance. Asthma symptoms include recurrent episodes of breathlessness (e.g., shortness of breath or dyspnea), wheezing, chest tightness, and cough.
Emphysema is a type of COPD often characterized by the alteration of lung tissue surrounding or adjacent to the airways in the lungs. Emphysema can involve destruction of lung tissue (e.g., alveoli tissue such as the alveolar sacs) that leads to reduced gas exchange and reduced radial traction applied to the airway wall by the surrounding lung tissue. The destruction of alveoli tissue leaves areas of emphysematous lung with overly large airspaces that are devoid of alveolar walls and alveolar capillaries and are thereby ineffective at gas exchange. Air becomes “trapped” in these larger airspaces. This “trapped” air may cause over-inflation of the lung, and in the confines of the chest restricts the in-flow of oxygen rich air and the proper function of healthier tissue. This results in significant breathlessness and may lead to low oxygen levels and high carbon dioxide levels in the blood. This type of lung tissue destruction occurs as part of the normal aging process, even in healthy individuals. Unfortunately, exposure to chemicals or other substances (e.g., tobacco smoke) may significantly accelerate the rate of tissue damage or destruction. Breathlessness may be further increased by airway obstruction. The reduction of radial traction may cause the airway walls to become “floppy” such that the airway walls partially or fully collapse during exhalation. An individual with emphysema may be unable deliver air out of their lungs due to this airway collapse and airway obstructions during exhalation.
Chronic bronchitis is a type of COPD that can be characterized by contraction of the airway smooth muscle, smooth muscle hypertrophy, excessive mucus production, mucous gland hypertrophy, and inflammation of airway walls. Like asthma, these abnormalities are the result of a complex interplay of local inflammatory cytokines, inhaled irritants, systemic hormones, local nervous system, and the central nervous system. Unlike asthma where respiratory obstruction may be largely reversible, the airway obstruction in chronic bronchitis is primarily chronic and permanent. It is often difficult for a chronic bronchitis sufferer to breathe because of chronic symptoms of shortness of breath, wheezing, and chest tightness, as well as a mucus producing cough.
Different techniques can be used to assess the severity and progression of pulmonary diseases. For example, pulmonary function tests, exercise capacity, and quality of life questionnaires are often used to evaluate subjects. Pulmonary function tests involve objective and reproducible measures of basic physiologic lung parameters, such as total airflow, lung volume, and gas exchange. Indices of pulmonary function tests used for the assessment of obstructive pulmonary diseases include the forced expiratory volume in 1 second (FEV1), the forced vital capacity (FVC), the ratio of the FEV1 to FVC, the total lung capacity (TLC), airway resistance and the testing of arterial blood gases. The FEV1 is the volume of air a patient can exhale during the first second of a forceful exhalation which starts with the lungs completely filled with air. The FEV1 is also the average flow that occurs during the first second of a forceful exhalation. This parameter may be used to evaluate and determine the presence and impact of any airway obstruction. The FVC is the total volume of air a patient can exhale during a forceful exhalation that starts with the lungs completely filled with air. The FEV1/FVC is the fraction of all the air that can be exhaled during a forceful exhalation during the first second. An FEV1/FVC ratio less than 0.7 after the administration of at least one bronchodilator defines the presence of COPD. The TLC is the total amount of air within the lungs when the lungs are completely filled and may increase when air becomes trapped within the lungs of patients with obstructive lung disease. Airway resistance is defined as the pressure gradient between the alveoli and the mouth to the rate of air flow between the alveoli and the mouth. similarly, resistance of a given airway would be defined as the ratio of the pressure gradient across the given airway to the flow through the airway. Arterial blood gases tests measure the amount of oxygen and the amount of carbon dioxide in the blood and are the most direct method for assessing the ability of the lungs and respiratory system to bring oxygen from the air into the blood and to get carbon dioxide from the blood out of the body.
Exercise capacity tests are objective and reproducible measures of a patient's ability to perform activities. A six minute walk test (6 MWT) is an exercise capacity test in which a patient walks as far as possible over a flat surface in 6 minutes. Another exercise capacity test involves measuring the maximum exercise capacity of a patient. For example, a physician can measure the amount of power the patient can produce while on a cycle ergometer. The patient can breathe 30 percent oxygen and the work load can increase by 5-10 watts every 3 minutes.
Quality of life questionnaires assess a patient's overall health and well being. The St. George's Respiratory Questionnaire is a quality of life questionnaire that includes 75 questions designed to measure the impact of obstructive lung disease on overall health, daily life, and perceived well-being. The efficacy of a treatment for pulmonary diseases can be evaluated using pulmonary function tests, exercise capacity tests, and/or questionnaires. A treatment program can be modified based on the results from these tests and/or questionnaires.
Treatments, such as bronchial thermoplasty, involve destroying smooth muscle tone by ablating the airway wall in a multitude of bronchial branches within the lung thereby eliminating both smooth muscles and nerves in the airway walls of the lung. The treated airways are unable to respond favorably to inhaled irritants, systemic hormones, and both local and central nervous system input. Unfortunately, this destruction of smooth muscle tone and nerves in the airway wall may therefore adversely affect lung performance. For example, inhaled irritants, such as smoke or other noxious substances, normally stimulate lung irritant receptors to produce coughing and contracting of airway smooth muscle. Elimination of nerves in the airway walls removes both local nerve function and central nervous input, thereby eliminating the lung's ability to expel noxious substances with a forceful cough. Elimination of airway smooth muscle tone may eliminate the airways' ability to constrict, thereby allowing deeper penetration of unwanted substances, such as noxious substances, into the lung.
Additionally, methods of destroying smooth muscle tone by ablating portions of the airway wall, such as bronchial thermoplasty, often have the following limitations: 1) inability to affect airways that are not directly ablated, typically airways smaller than approximately 3.0 mm which may also be narrowed in obstructive lung diseases such as asthma, emphysema, and chronic bronchitis; 2) short-term swelling that causes acute respiratory problems due to perioperative swelling in airways already narrowed by obstructive lung disease effects; 3) hundreds of applications to airways within the lungs may be required to alter overall lung functionality; 4) since multiple generations of airways within the lung are treated (typically generations 2-8), targeting lung airways without missing or over treating specific lung airway sections can be problematic; and, 5) separating the treating step into stages may be required to reduce the healing load on the lung which adds additional risk and cost with each additional bronchoscopy treatment session.
Both asthma and COPD are serious diseases with growing numbers of sufferers. Current management techniques, which include prescription drugs, are neither completely successful nor free from side effects. Additionally, many patients do not comply with their drug prescription dosage regiment. Accordingly, it would be desirable to provide a treatment which improves resistance to airflow without the need for patient compliance.
In some embodiments, a treatment system can be navigated through airways, such as the right and left main bronchi of the lung root as well as more distal airways within the lungs, to treat a wide range of pulmonary symptoms, conditions, and/or diseases, including, without limitation, asthma, COPD, obstructive lung diseases, or other diseases that lead to an increased resistance to airflow in the lungs. The treatment system can treat one or more target sites without treating non-targeted sites. Even if targeted anatomical features (e.g., nerves, glands, membranes, and the like) of main bronchi, lobar bronchi, segmental bronchi or subsegmental bronchi are treated, non-targeted anatomical features can be substantially unaltered. For example, the treatment system can destroy nerve tissue at target sites without destroying to any significant extent non-targeted tissue that can remain functional after performing treatment.
At least some embodiments disclosed herein can be used to affect nerve tissue of nerve trunks outside of airway walls while maintaining the airways ability to move (e.g., constrict and/or expand) in response to, for example, inhaled irritants, local nerve stimulation, systemic hormones, or combinations thereof. In some embodiments, the nerve tissue of nerve trunks is destroyed without eliminating smooth muscle tone. After damaging the nerve trunks, the airways have at least some muscle tone such that the smooth muscles in the airways, if stimulated, can alter the diameter of the airway to help maintain proper lung function. A wide range of different physiological functions associated with smooth muscle tone can be maintained before, during, and/or after the treatment.
In some embodiments, a method for treating one or more pulmonary diseases is provided. The method includes damaging nerve tissue of a vagal nerve trunk extending along the outside of a bronchial tree airway so as to attenuate nervous system signals transmitted to a portion of the bronchial tree. The nerve trunk may be the main stem of a nerve, comprising a bundle of nerve fibers bound together by a tough sheath of connective tissue. In some embodiments, the nerve tissue is damaged while maintaining a functionality of one or more anatomical features, such as blood vessels, also extending alongside the airway so as to preserve a respiratory function of the portion of the bronchial tree after the nerve tissue is damaged.
Conditions and symptoms associated with pulmonary diseases can be reduced, limited, or substantially eliminated. For example, airway obstruction can be treated to elicit reduced airflow resistance. Blood vessels or other tissue can remain intact and functional during and/or after treatment. The respiratory function that is preserved can include gas exchange, mucociliary transport, and the like. In some embodiments, the nerve tissue, such as nerve tissue of nerve trunks located outside of the airway, is damaged without damaging to any significant extent a portion of the airway wall that is circumferentially adjacent to the damaged nerve tissue. Accordingly, non-targeted tissue can be substantially unaltered by the damage to the airway nerve tissue.
Damaging the nerve tissue can involve delivering energy to the nerve tissue such that the destroyed nerve tissue impedes or stops the transmission of nervous system signals to nerves more distal along the bronchial tree. The nerve tissue can be temporarily or permanently damaged by delivering different types of energy to the nerve tissue. For example, the nerve tissue can be thermally damaged by increasing a temperature of the nerve tissue to a first temperature (e.g., an ablation temperature) while the wall of the airway is at a second temperature that is less than the first temperature. In some embodiments, a portion of the airway wall positioned radially inward from the nerve tissue can be at the first temperature so as to prevent permanent damage to the portion of the airway wall. The first temperature can be sufficiently high to cause permanent destruction of the nerve tissue. In some embodiments, the nerve tissue is part of a nerve trunk located in connective tissue outside of the airway wall. The smooth muscle and nerve tissue in the airway wall can remain functional to maintain a desired level of smooth muscle tone. The airway can constrict/dilate in response to stimulation (e.g., stimulation caused by inhaled irritants, the local nervous system, or systemic hormones). In other embodiments, the nerve tissue is part of a nerve branch or nerve fibers in the airway wall. In yet other embodiments, both nerve tissue of the nerve trunk and nerve tissue of nerve branches/fibers are simultaneously or sequentially damaged. Various types of activatable elements, such as ablation elements, can be utilized to output the energy.
In some embodiments, a method for treating a subject comprises moving an elongate assembly along a lumen of an airway of a bronchial tree. The airway includes a first tubular section, a second tubular section, a treatment site between the first tubular section and the second tubular section, and a nerve extending along at least the first tubular section, the treatment site, and the second tubular section. The nerve can be within or outside of the airway wall. In some embodiments, the nerve is a nerve trunk outside of the airway wall and connected to a vagus nerve.
The method can further include damaging a portion of the nerve at the treatment site to substantially prevent signals from traveling between the first tubular section and the second tubular section via the nerve. In some embodiments, blood flow between the first tubular section and the second tubular section can be maintained while damaging a portion of the nerve. The continuous blood flow can maintain desired functioning of distal lung tissue.
The second tubular section of the airway may dilate in response to the damage to the nerve. Because nervous system signals are not delivered to smooth muscle of the airway of the second tubular section, smooth muscle can relax so as to cause dilation of the airway, thereby reducing airflow resistance, even airflow resistance associated with pulmonary diseases. In some embodiments, nerve tissue can be damaged to cause dilation of substantially all the airways distal to the damaged tissue. The nerve can be a nerve trunk, nerve branch, nerve fibers, and/or other accessible nerves.
The method, in some embodiments, includes detecting one or one attributes of an airway and evaluating whether the nerve tissue is damaged based on the attributes. Evaluating includes comparing measured attributes of the airway (e.g., comparing measurements taken at different times), comparing measured attributes and stored values (e.g., reference values), calculating values based on measured attributes, monitoring changes of attributes, combinations thereof, or the like.
In some embodiments, a method for treating a subject includes moving an intraluminal device along a lumen of an airway of a bronchial tree. A portion of the airway is denervated using the intraluminal device. In some embodiments, the portion of the airway is denervated without irreversibly damaging to any significant extent an inner surface of the airway. In some embodiments, a portion of a bronchial tree is denervated without irreversibly damaging to any significant extent nerve tissue (e.g., nerve tissue of nerve fibers) within the airway walls of the bronchial tree. The inner surface can define the lumen along which the intraluminal device was moved.
The denervating process can be performed without destroying at least one artery extending along the airway. In some embodiments, substantially all of the arteries extending along the airway are preserved during the denervating process. In some embodiments, one or more nerves embedded in the wall of the airway can be generally undamaged during the denervating process. The destroyed nerves can be nerve trunks outside of the airway.
In some embodiments, the denervating process can decrease smooth muscle tone of the airway to achieve a desired increased airflow into and out of the lung. In some embodiments, the denerving process causes a sufficient decrease of smooth muscle tone so as to substantially increase airflow into and out of the lung. For example, the subject may have an increase in FEV1 of at least 10% over a baseline FEV1. As such, the subject may experience significant improved lung function when performing normal everyday activities, even strenuous activities. In some embodiments, the decrease of airway smooth muscle tone is sufficient to cause an increase of FEV1 in the range of about 10% to about 30%. Any number of treatment sites can be treated either in the main bronchi, segmental bronchi or subsegmental bronchi to achieve the desired increase in lung function.
In some embodiments, an elongate assembly for treating a lung is adapted to damage nerve tissue of a nerve trunk so as to attenuate nervous system signals transmitted to a more distal portion of the bronchial tree. The tissue can be damaged while the elongated assembly extends along a lumen of the bronchial tree. A delivery assembly can be used to provide access to the nerve tissue.
In some other embodiments, a system for treating a subject includes an elongate assembly dimensioned to move along a lumen of an airway of a bronchial tree. The elongate assembly is adapted to attenuate signals transmitted by nerve tissue, such as nerve tissue of nerve trunks, while not irreversibly damaging to any significant extent an inner surface of the airway. The elongate assembly can include an embeddable distal tip having at least one actuatable element, such as an ablation element. The ablation element can ablate various types of nerve tissue when activated. In some embodiments, the ablation element includes one or more electrodes operable to output radiofrequency energy.
In some embodiments, a method comprises damaging nerve tissue of a first main bronchus to substantially prevent nervous system signals from traveling to substantially all distal bronchial branches connected to the first main bronchus. In some embodiments, most or all of the bronchial branches distal to the first main bronchus are treated. The nerve tissue, in certain embodiments, is positioned between a trachea and a lung through which the bronchial branches extend. The method further includes damaging nerve tissue of a second main bronchus to substantially prevent nervous system signals from traveling to substantially all distal bronchial branches connected to the second main bronchus. A catheter assembly can be used to damage the nerve tissue of the first main bronchus and to damage the nerve tissue of the second main bronchus without removing the catheter assembly from a trachea connected to the first and second bronchi.
In some embodiments, a method comprises denervating most of a portion of a bronchial tree to substantially prevent nervous system signals from traveling to substantially all bronchial branches of the portion. In certain embodiments, denervating procedures involve damaging nerve tissue using less than about 100 applications of energy, 50 applications of energy, 36 applications of energy, 18 applications of energy, 10 applications of energy, or 3 applications of energy. Each application of energy can be at a different treatment site. In some embodiments, substantially all bronchial branches in one or both lungs are denervated by the application of energy.
In certain embodiments, one or more detection elements are used to detect attributes of airways before, during, and/or after therapy. A detection element can physically contact an inner surface of the airway to evaluate physical properties of the airway. The detection element may include one or more inflatable balloons that can be positioned distal to targeted tissue
In the Figures, identical reference numbers identify similar elements or acts.
In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the invention. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures associated with catheter systems, delivery assemblies, activatable elements, circuitry, and electrodes have not been described in detail to avoid unnecessarily obscuring descriptions of the embodiments of the invention.
Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including but not limited to.”
The left and right vagus nerves 41, 42 originate in the brainstem, pass through the neck, and descend through the chest on either side of the trachea 20. The vagus nerves 41, 42 spread out into nerve trunks 45 that include the anterior and posterior pulmonary plexuses that wrap around the trachea 20, the left main bronchus 21, and the right main bronchus 22. The nerve trunks 45 also extend along and outside of the branching airways of the bronchial tree 27. Nerve trunks 45 are the main stem of a nerve, comprising a bundle of nerve fibers bound together by a tough sheath of connective tissue.
The prime function of the lungs 10 is to exchange oxygen from air into the blood and to exchange carbon dioxide from the blood to the air. The process of gas exchange begins when oxygen rich air is pulled into the lungs 10. Contraction of the diaphragm and intercostal chest wall muscles cooperate to decrease the pressure within the chest to cause the oxygen rich air to flow through the airways of the lungs 10. For example, air passes through the mouth and nose, the trachea 20, then through the bronchial tree 27. The air is ultimately delivered to the alveolar air sacs for the gas exchange process.
Oxygen poor blood is pumped from the right side of the heart through the pulmonary artery 30 and is ultimately delivered to alveolar capillaries. This oxygen poor blood is rich in carbon dioxide waste. Thin semi-permeable membranes separate the oxygen poor blood in capillaries from the oxygen rich air in the alveoli. These capillaries wrap around and extend between the alveoli. Oxygen from the air diffuses through the membranes into the blood, and carbon dioxide from the blood diffuses through the membranes to the air in the alveoli. The newly oxygen enriched blood then flows from the alveolar capillaries through the branching blood vessels of the pulmonary venous system to the heart. The heart pumps the oxygen rich blood throughout the body. The oxygen spent air in the lung is exhaled when the diaphragm and intercostal muscles relax and the lungs and chest wall elastically return to the normal relaxed states. In this manner, air can flow through the branching bronchioles, the bronchi 21, 22, and the trachea 20 and is ultimately expelled through the mouth and nose.
A treatment system 198 of
In some embodiments, the treatment system 198 targets the nervous system which provides communication between the brain and the lungs 10 using electrical and chemical signals. A network of nerve tissue of the autonomic nervous system senses and regulates activity of the respiratory system and the vasculature system. Nerve tissue includes fibers that use chemical and electrical signals to transmit sensory and motor information from one body part to another. For example, the nerve tissue can transmit motor information in the form of nervous system input, such as a signal that causes contraction of muscles or other responses. The fibers can be made up of neurons. The nerve tissue can be surrounded by connective tissue, i.e., epineurium. The autonomic nervous system includes a sympathetic system and a parasympathetic system. The sympathetic nervous system is largely involved in “excitatory” functions during periods of stress. The parasympathetic nervous system is largely involved in “vegetative” functions during periods of energy conservation. The sympathetic and parasympathetic nervous systems are simultaneously active and generally have reciprocal effects on organ systems. While innervation of the blood vessels originates from both systems, innervation of the airways are largely parasympathetic in nature and travel between the lung and the brain in the right vagus nerve 42 and the left vagus nerve 41.
The treatment system 198 can perform any number of procedures on one or more of these nerve trunks 45 to affect the portion of the lung associated with those nerve trunks. Because some of the nerve tissue in the network of nerve trunks 45 coalesce into other nerves (e.g., nerves connected to the esophagus, nerves though the chest and into the abdomen, and the like), the treatment system 198 can treat specific sites to minimize, limit, or substantially eliminate unwanted damage of those other nerves. Some fibers of anterior and posterior pulmonary plexuses coalesce into small nerve trunks which extend along the outer surfaces of the trachea 20 and the branching bronchi and bronchioles as they travel outward into the lungs 10. Along the branching bronchi, these small nerve trunks continually ramify with each other and send fibers into the walls of the airways, as discussed in connection with
The treatment system 198 can affect specific nerve tissue, such as vagus nerve tissue, associated with particular sites of interest. Vagus nerve tissue includes efferent fibers and afferent fibers oriented parallel to one another within a nerve branch. The efferent nerve tissue transmits signals from the brain to airway effector cells, mostly airway smooth muscle cells and mucus producing cells. The afferent nerve tissue transmits signals from airway sensory receptors, which respond variously to irritants and stretch, to the brain. While efferent nerve tissue innervates smooth muscle cells all the way from the trachea 20 to the terminal bronchioles, the afferent fiber innervation is largely limited to the trachea 20 and larger bronchi. There is a constant, baseline tonic activity of the efferent vagus nerve tissues to the airways which causes a baseline level of smooth muscle contraction and mucous secretion.
The treatment system 198 can affect the efferent and/or the afferent tissues to control airway smooth muscle (e.g., innervate smooth muscle) and mucous secretion. The contraction of airway smooth muscle and excess mucous secretion associated with pulmonary diseases often results in relatively high air flow resistance causing reduced gas exchange and decreased lung performance.
For example, the treatment system 198 can attenuate the transmission of signals traveling along the vagus nerves 41, 42 that cause muscle contractions, mucus production, and the like. Attenuation can include, without limitation, hindering, limiting, blocking, and/or interrupting the transmission of signals. For example, the attenuation can include decreasing signal amplitude of nerve signals or weakening the transmission of nerve signals. Decreasing or stopping nervous system input to distal airways can alter airway smooth muscle tone, airway mucus production, airway inflammation, and the like, thereby controlling airflow into and out of the lungs 10. In some embodiments, the nervous system input can be decreased to correspondingly decrease airway smooth muscle tone. In some embodiments, the airway mucus production can be decreased a sufficient amount to cause a substantial decrease in coughing and/or in airflow resistance. Signal attenuation may allow the smooth muscles to relax and prevent, limit, or substantially eliminate mucus production by mucous producing cells. In this manner, healthy and/or diseased airways can be altered to adjust lung function. After treatment, various types of questionnaires or tests can be used to assess the subject's response to the treatment. If needed or desired, additional procedures can be performed to reduce the frequency of coughing, decrease breathlessness, decrease wheezing, and the like.
Main bronchi 21, 22 (i.e., airway generation 1) of
In some embodiments, one of the left and right main bronchi 21, 22 is treated to treat one side of the bronchial tree 27. The other main bronchus 21, 22 can be treated based on the effectiveness of the first treatment. For example, the left main bronchus 21 can be treated to treat the left lung 11. The right main bronchus 22 can be treated to treat the right lung 12. In some embodiments, a single treatment system can damage the nerve tissue of one of the bronchi 21, 22 and can damage the nerve tissue of the other main bronchus 21, 22 without removing the treatment system from the trachea 20. Nerve tissue positioned along the main bronchi 21, 22 can thus be damaged without removing the treatment system from the trachea 20. In some embodiments, a single procedure can be performed to conveniently treat substantially all, or at least a significant portion (e.g., at least 50%, 70%, 80%, 90% of the bronchial airways), of the patient's bronchial tree. In other procedures, the treatment system can be removed from the patient after treating one of the lungs 11, 12. If needed, the other lung 11, 12 can be treated in a subsequent procedure.
The treatment system 198 of
The treatment system 198 can also be used in segmental or subsegmental bronchi. Each segmental bronchus may be treated by delivering energy to a single treatment site along each segmental bronchus. For example, energy can be delivered to each segmental bronchus of the right lung. In some procedures, ten applications of energy can treat most of or substantially all of the right lung. In some procedures, most or substantially all of both lungs are treated using less than thirty-six different applications of energy. Depending on the anatomical structure of the bronchial tree, segmental bronchi can often be denervated using one or two applications of energy.
The treatment system 198 can affect nerve tissue while maintaining function of other tissue or anatomical features, such as the mucous glands, cilia, smooth muscle, body vessels (e.g., blood vessels), and the like. Nerve tissue includes nerve cells, nerve fibers, dendrites, and supporting tissue, such as neuroglia. Nerve cells transmit electrical impulses, and nerve fibers are prolonged axons that conduct the impulses. The electrical impulses are converted to chemical signals to communicate with effector cells or other nerve cells. By way of example, the treatment system 198 is capable of denervating a portion of an airway of the bronchial tree 27 to attenuate one or more nervous system signals transmitted by nerve tissue. Denervating can include damaging all of the nerve tissue of a section of a nerve trunk along an airway to stop substantially all of the signals from traveling through the damaged section of the nerve trunk to more distal locations along the bronchial tree. If a plurality of nerve trunks extends along the airway, each nerve trunk can be damaged. As such, the nerve supply along a section of the bronchial tree can be cut off. When the signals are cut off, the distal airway smooth muscle can relax leading to airway dilation. This airway dilation reduces airflow resistance so as to increase gas exchange in the lungs 10, thereby reducing, limiting, or substantially eliminating one or more symptoms, such as breathlessness, wheezing, chest tightness, and the like. Tissue surrounding or adjacent to the targeted nerve tissue may be affected but not permanently damaged. In some embodiments, for example, the bronchial blood vessels along the treated airway can deliver a similar amount of blood to bronchial wall tissues and the pulmonary blood vessels along the treated airway can deliver a similar amount of blood to the alveolar sacs at the distal regions of the bronchial tree 27 before and after treatment. These blood vessels can continue to transport blood to maintain sufficient gas exchange. In some embodiments, airway smooth muscle is not damaged to a significant extent. For example, a relatively small section of smooth muscle in an airway wall which does not appreciably impact respiratory function may be reversibly altered. If energy is used to destroy the nerve tissue outside of the airways, a therapeutically effective amount of energy does not reach a significant portion of the non-targeted smooth muscle tissue.
The treatment system 198 of
The controller 202 of
In some embodiments, the controller 202 has a closed loop system or an open loop system. For example, the controller 202 can have a closed loop system, whereby the power to the distal tip 203 is controlled based upon feedback signals from one or more sensors configured to transmit (or send) one or more signals indicative of one or more tissue characteristics, energy distribution, tissue temperature, or any other measurable parameters of interest. Based on those readings, the controller 202 can then adjust operation of the distal tip 203. Alternatively, the treatment system 198 can be an open loop system wherein the operation of the distal tip 203 is set by user input. For example, the treatment system 198 may be set to a fixed power mode. It is contemplated that the treatment system 198 can be repeatedly switched between a closed loop system and an open loop system to treat different types of sites.
The distal tip 203 of
The distal tip 203 of
In some embodiments, the distal tip 203 selectively treats targeted treatment sites inside of the airway wall 103 (e.g., anatomical features in the stromas 112a, 112b). For example, the mucous glands 116 can be damaged to reduce mucus production a sufficient amount to prevent the accumulation of mucus that causes increased air flow resistance while preserving enough mucus production to maintain effective mucociliary transport, if needed or desired. In some embodiments, for example, the distal tip 203 outputs ablative energy that travels through the inner periphery of the airway wall 103 to the mucous glands 116. In other embodiments, the distal tip 203 is inserted into the airway wall 103 to position the distal tip 203 next to the mucous glands 116. The embedded distal tip 203 then treats the mucous glands 116 while limiting treatment of surrounding tissue. The distal tip 203 can also be used to destroy nerve branches/fibers passing through the airway wall 103 or other anatomical features in the airway wall 103.
If the airway 100 is overly constricted, the air flow resistance of the airway 100 may be relatively high. The distal tip 203 can relax the muscle tissue 114 to dilate the airway 100 to reduce air flow resistance, thereby allowing more air to reach the alveolar sacs for the gas exchange process. Various airways of the bronchial tree 47 may have muscles that are constricted in response to signals traveling through the nerve trunks 45. The tip 203 can damage sites throughout the lungs 10 to dilate constricted airways.
The distal tip 203 of
In some embodiments, a fluid (e.g., a liquid, gas, or mixtures thereof) is employed to damage tissue. The distal tip 203 can include one or more flow elements through which the fluid can circulate to control the surface temperature of the flow element. The flow element can be one or more balloons, expandable members, and the like. The fluid can be heated/cooled saline, cryogenic fluids, and the like. Additionally or alternatively, the distal tip 203 can include one or more ports through which fluid flows to traumatize tissue.
In some embodiments, the distal tip 203 delivers one or more substances (e.g., radioactive seeds, radioactive materials, etc.), treatment agents, and the like. Exemplary non-limiting treatment agents include, without limitation, one or more antibiotics, anti-inflammatory agents, pharmaceutically active substances, bronchoconstrictors, bronchodilators (e.g., beta-adrenergic agonists, anticholinergics, etc.), nerve blocking drugs, photoreactive agents, or combinations thereof. For example, long acting or short acting nerve blocking drugs (e.g., anticholinergics) can be delivered to the nerve tissue to temporarily or permanently attenuate signal transmission. Substances can also be delivered directly to the nerves 122 or the nerve trunks 45, or both, to chemically damage the nerve tissue.
Referring to
The shaft 500 can be a generally straight shaft that is bent as it moves along the lumen 401. In some embodiments, the shaft 500 has a preformed non-linear section 503 to direct the ablation assembly 520 towards the airway wall 103. As shown in
In some embodiments, the shaft 500 selectively moves between a delivery configuration and a treatment configuration. For example, the shaft 500 can have a substantially straight configuration for delivery and a curved configuration for engaging tissue. In such embodiments, the shaft 500 can be made, in whole or in part, of one or more shape memory materials, which move the shaft 500 between the delivery configuration and the treatment configuration when activated. Shape memory materials include, for example, shape memory alloys (e.g., NiTi), shape memory polymers, ferromagnetic materials, and the like. These materials can be transformed from a first preset configuration to a second preset configuration when activated (e.g., thermally activated).
The ablation assembly 520 includes a protective section 524 and an ablation element 525. When the ablation element 525 is activated, the ablation element 525 outputs energy to targeted tissue. The protective section 524 inhibits or blocks the outputted energy to protect non-targeted tissue. The ablation element 525 and the protective section 524 thus cooperate to provide localized delivery of energy to minimize, limit, or substantially eliminate unwanted ancillary trauma associated with the outputted energy.
The ablation element 525 can be adapted to output energy that ablates tissue. The terms “ablate” or “ablation,” including derivatives thereof, include, without limitation, substantial altering of electrical properties, mechanical properties, chemical properties, or other properties of tissue. In the context of pulmonary ablation applications shown and described with reference to the variations of the illustrative embodiments herein, “ablation” includes sufficiently altering of nerve tissue properties to substantially block transmission of electrical signals through the ablated nerve tissue.
The term “element” within the context of “ablation element” includes a discrete element, such as an electrode, or a plurality of discrete elements, such as a plurality of spaced apart electrodes, which are positioned so as to collectively treat a region of tissue or treat discrete sites. One type of ablation element emits energy that ablates tissue when the element is coupled to and energized by an energy source. Example energy emitting ablation elements include, without limitation, electrode elements coupleable to direct current (“DC”) sources or alternating current (“AC”) sources (e.g., radiofrequency (“RF”) current sources), antenna elements energizable by microwave energy sources, pulsed high voltage sources, heating elements (e.g., metallic elements or other thermal conductors which are energized to emit heat via convective heat transfer, conductive heat transfer, etc.), light emitting elements (e.g., fiber optics capable of transmitting light sufficient to ablate tissue when the fiber optics are coupled to a light source), light sources (e.g., lasers, light emitting diodes, etc.), ultrasonic elements such as ultrasound elements adapted to emit ultrasonic sound waves sufficient to ablate tissue when coupled to suitable excitation sources), combinations thereof, and the like.
As used herein, the term “ablate,” including variations thereof, is construed to include, without limitation, to destroy or to permanently damage, injure, or traumatize tissue. For example, ablation may include localized tissue destruction, cell lysis, cell size reduction, necrosis, or combinations thereof.
In some embodiments, the ablation assembly 520 can be connected to an energy generator (e.g., a radiofrequency (RF) electrical generator) by electrical cables within the shaft 500. For example, the RF electrical generator can be incorporated into the controller 202 of
RF energy can be outputted at a desired frequency based on the treatment. Example frequencies include, without limitation, frequencies in the range of about 50 KHZ to about 1000 MHZ. When the RF energy is directed into tissue, the energy is converted within the tissue into heat causing the temperature of the tissue to be in the range of about 40° C. to about 99° C. The RF energy can be applied for a length of time in the range of about 1 second to about 120 seconds. In some embodiments, the RF generator has a single channel and delivers approximately 1 to 25 watts of RF energy and possesses continuous flow capability. Other ranges of frequencies, time internals, and power outputs can also be used.
The protective section 524 can be in the form of a shield made, in whole or in part, of a material that is non-transmissive with respect to the energy from the ablation element 525. In some embodiments, the protective section 524 is comprised of one or more metals, optically opaque materials, and the like. If the ablation element 525 outputs ablative energy, the protective section 524 can block a sufficient amount of the ablative energy to prevent ablation of tissue directly next to the protective section 524. In this manner, non-targeted tissue is not permanently damaged.
A user can visually inspect the airway 100 using the delivery assembly 400 of
As shown in
The illustrated ablation assembly 520 is connected to one lead of the RF generator and the other lead of the RF generator may be connected to an external electrode. When the RF generator is activated, the ablation element 525 delivers RF energy to tissue contacting or adjacent to the ablation element 525. RF energy flows through the tissue and is converted into heat. The heat can be concentrated in the outer portion of the airway wall 103. For example, the ablation element 525 of
Natural body functions can help prevent, reduce, or limit damage to tissue. If the bronchial artery branches 130 are heated by the treatment system 198A, blood within the blood vessels 130 can absorb the thermal energy and can then carry the thermal energy away from the heated section of the branches 130. In this manner, thermal energy is transferred to the blood. After the treatment is performed, the bronchial artery branches 130 can continue to maintain the health of lung tissue.
This procedure may be repeated to damage additional tissue of nerve trunks 45 located outside the circumference of the wall 103. In some embodiments, all the nerves about the airway 100 can be treated to prevent signals from passing between a proximal section 571 of the airway 100 and distal section 573 of the airway 100, as shown in
Treatment efficacy can be evaluated based at least in part on one or more airway attributes, pulmonary function tests, exercise capacity tests, and/or questionnaires. Patients can be evaluated to track and monitor their progress. If needed or desired, additional procedures can be performed until desired responses are achieved.
Different types of instruments for evaluating airway attributes may be used with treatment systems. During ablation, feedback from an instrument can indicate whether the targeted tissue has been ablated. Once targeted tissue is ablated, therapy can be discontinued to minimize or limit collateral damage, if any, to healthy untargeted tissue.
The attributes of airways evaluated by the instrument may include, without limitation, physical properties of airways (e.g., airway compliance, contractile properties, etc.), airway resistance, dimensions of airway lumens (e.g., shapes of airways, diameters of airways, etc.), responsiveness of airways (e.g., responsiveness to stimulation), muscle characteristics (e.g., muscle tone, muscle tension, etc.), or the like. In some embodiments, changes of airway muscle characteristics can be monitored by measuring pressure changes the intraluminal balloon that is inflated to a known pressure. Based on pressure changes in the balloon, a physician determines the effects, if any, of the treatment, including, without limitation, whether targeted tissue has been stimulated, damaged, ablated, or the like. For example, the balloon can be positioned distal to the targeted tissue. As nerve tissue is damaged, muscle tension in the airway surrounding the balloon is reduced causing expansion of the airway, as well as expansion of the balloon. The pressure in the balloon decreases as the balloon expands.
The instrument 199 and the treatment system 198 can be delivered through different lumens in a delivery device, including, without limitation, a multi-lumen catheter, a delivery sheath, bronchoscope, an endoscope, or other suitable device for delivering and guiding multiple devices. The delivery device can be selected based on the location of the treatment site(s), configuration of the treatment system, or the like.
Decreases in airway resistance may indicate that passageways of airways are opening, for example, in response to attenuation of nervous system input to those airways. The decrease of airway resistance associated with treating low generation airways (e.g., main bronchi, lobar bronchi, segmental bronchi) may be greater than the amount of decrease of airway resistance associated with treating high generation airways (e.g., subsegmental bronchioles). A physician can select appropriate airways for treatment to achieve a desired decrease in airway resistance and can be measured at a patient's mouth, a bronchial branch that is proximate to the treatment site, a trachea, or any other suitable location. The airway resistance can be measured before performing the therapy, during the therapy, and/or after the therapy. In some embodiments, airway resistance is measured at a location within the bronchial tree by, for example, using a vented treatment system that allows for respiration from areas that are more distal to the treatment site.
Each electrode assembly 620 includes a sharp tip for piercing the airway wall 103 and includes extendable and retractable sharp ablation elements 625. The ablation assemblies 620 are preferably insulated except for the exposed ablation elements 625. The ablation assemblies 620 can be connected to a RF electrical generator by electrical cables that travel within the shaft 610. While the treatment system 198B is being delivered, the ablation assemblies 620 may be positioned within the shaft 610. The ablation assemblies 620 can be moved out of the shaft 610 and brought into contact with the wall 103. The ablation assemblies 620 can be simultaneously moved through the airway wall 103 until desired lengths of the ablation elements 625 are within the airway wall 103.
As shown in
All of the ablation assemblies 620 can be connected to one lead of the RF generator and the other lead of the RF generator may be connected to an external electrode 623 (shown in phantom), so that current flows between the ablation assemblies 620 and/or between one or more of the ablation assemblies 620 and the external electrode 623. In some embodiments, a selected number of the ablation assemblies 620 are connect to one lead of the RF generator while the other ablation assemblies 620 are connected to the other lead of the RF generator such that current flows between the ablation assemblies 620.
When the RF generator is activated, current flows through the tissue and generates a desired amount of heat. The heat can be concentrated on the outside of the airway wall 103 to damage peripheral tissue. For example, the temperature of the connective tissue can be higher than the temperatures of the stroma, smooth muscles, and/or the epithelium. By way of example, the temperature of the connective tissue can be sufficiently high to cause damage to the nerve tissues in the nerve trunks 45 while other non-targeted tissues of the airway 100 are kept at a lower temperature to prevent or limit damage to the non-targeted tissues. In other embodiments, heat can be concentrated in one or more of the internal layers (e.g., the stroma) of the airway wall 103 or in the inner periphery (e.g., the epithelium) of the airway wall 103.
As shown in
The ablation assemblies 720 can include protective sections 721 and the exposed ablation elements 725. The protective sections 721 can extend from the shaft 710 to an inner surface of the airway 100. The ablation elements 725 protrude from corresponding protective sections 721. The ablation assemblies 720 can be connected to a radiofrequency (RF) electrical generator by electrical cables that travel within the shaft 710.
The treatment system 198C is delivered to the desired treatment location within the airway 100. While the treatment system 198C is being delivered, the ablation assemblies 720 are retracted within the shaft 710 so as not to damage the airway 100 or the delivery device 400, or both. Once in position, the sharp ablation elements 725 are brought into contact with the airway wall 103. The elements 725 are then advanced through the airway wall 103 until the ablation elements 625 are embedded within the airway wall 103. Substantially all of the ablation assemblies 720 can be connected to one lead of the RF generator and the other lead of the RF generator may be connected to an external electrode, so that current flows between the ablation assemblies 720 and the external electrode. Alternatively, selected individual ablation assemblies 720 can be connect to one lead of the RF generator while other ablation assemblies 720 can be connected to the other lead of the RF generator, so that current can flow between the ablation assemblies 720.
When used, the delivery device 400A is advanced to the desired treatment region of the airway 100. The imaging device 850 is then used to image at least a portion of the airway wall 103, thereby locating the anatomical structures, such as the nerve trunks 45 and/or bronchial artery branches 130, which are located in the connective tissue 124 outside of the airway wall. For example, the imaging device 850 can be used to circumferentially image the airway 100. In some modes of operation, target tissues (e.g., the nerve trunks 45, mucous glands 116, and the like) are located such that only the portion of the wall 103 immediately adjacent to the target tissues and the connective tissue 124 are treated. In other modes of operation, the non-targeted tissues (e.g., bronchial artery branches 130) are localized and all other regions of the wall 103 and the connective tissue 124 are treated.
When treating the nerve trunks 45, the tip 413 of the delivery device 400A can be guided and positioned near a selected nerve trunk 45. Once in position, the sharp ablation element 525 is brought into contact with the wall 103. The ablation element 525 is then advanced through the wall 103 until the ablation elements 525 are embedded. The illustrated exposed ablation elements 525 are adjacent to the nerve trunk in the connective tissue 124. The RF generator is activated and current flows between the ablation assembly 520 and the tissue of the wall 103. The current causes the tissues of the nerve trunks 45 to increase in temperature until the heated tissue is damaged. By positioning the ablation assembly 520 near the nerve trunk 45, the nerve trunk 45 is selectively damaged while injury to non-targeted tissues, such as the bronchial arteries 130, is minimized. This procedure may be repeated to damage additional nerve branches 45 located around the circumference of the wall 103 in or adjacent to the connective tissue 124.
Various types of devices can be used to remotely treat target tissues.
The ultrasound transducer array 950 can emit highly focused sound waves 960 into the connective tissue 124 to damage the nerve trunks 45 and minimize or prevent injury to the bronchial arteries 130. The tip 413E of the bronchoscope 400B can be positioned such that the outputted energy is directed away from or does not reach the bronchial artery branches 130. This procedure of remotely treating tissue may be repeated to damage additional nerve trunks 45 located around the circumference of the wall 103 in the connective tissue 124, as desired. The bronchoscope 400B can be used to damage all or at least some of the nerve trunks 45 at a particular section of the airway 100.
The elongate assembly 200F of
The treatment system 2000 generally includes the expandable member 2002 (illustrated in the form of a distensible, thermally conductive balloon), an ablation electrode 2004, a conducting element 2031, an inflow line 2011, and an outflow line 2021. The ablation electrode 2004 is expandable and connected to a distal end 2033 of the conducting element 2031. A proximal end 2035 of the conducting element 2031 is connected to an electrical connector 2038. Energy is transferred from the electrical connector 2038 to the expandable electrode 2004 through the conducting element 2031. The conducting element 2031 can include, without limitation, one or more wires, conduits, or the like.
A proximal end 2009 of the inflow line 2011 has an inline valve 2012. A proximal end 2015 of the outflow line 2021 also has an outflow valve 2022. The inline valve 2011 can be connected to a fluid supply, such as a coolant source, by a connector 2018. Fluid flows through the inflow line 2011 into the balloon 2002, and exits the balloon 2002 via the outflow line 2021. The fluid can include, without limitation, temperature controlled fluid, such as water, saline, or other fluid suitable for use in a patient.
A lumen 2017 of the inflow line 2011 and a lumen 2019 of the outflow line 2021 provide fluid communication with the balloon 2002. Fluid can flow through the lumen 2017 into the balloon 2002. The fluid circulates within the balloon 2002 and flows out of the balloon 2002 via the lumen 2019. The fluid can pass through the connector 2028 to a fluid return system, which may cool the fluid and re-circulate the fluid to the fluid supply.
Different types of materials can be used to form different components of the system 2000. In some embodiments, the balloon 2002 is made, in whole or in part, of a distensible, chemically inert, non-toxic, electrically insulating, and thermally conductive material. For example, the balloon 2002 may be made of polymers, plastics, silicon, rubber, polyethylene, combinations thereof, or the like. In some embodiments, the inflow line 2011 and the outflow line 2021 are made, in whole or in part, of any suitable flexible, chemically inert, non-toxic material for withstanding operating pressures without significant expansion. The inflow line 2011 and the outflow line 2021 can have a suitable length to be passed into the lung and bronchial tree. For example, the lines 2011, 2021 can have a length of approximately 80 cm. Other lengths are also possible.
A tip 2005 protrudes from the balloon 2002. The illustrated tip 2005 is an atruamatic tip positioned opposite the end of the inflow line 2011. Near the tip 2005, the inflow line 2011 has an aperture 2013 that releases fluid into the balloon 2002. The fluid flows within the balloon 2002 and is collected into the outflow line 2021. The illustrated outflow line 2021 has an opening 2023 for receiving the fluid. The opening 2023 is generally at the distal end of a portion of the outflow line 2021 in the balloon 2002 and collects fluid from any direction. Because the openings 2013, 2023 are at opposite ends of the balloon 2002, fluid can flow in generally one direction through the balloon 2002. This ensures that fluid at a desired temperature fills the balloon 2002.
The shapes of the electrode 2004 and the balloon 2002 can be selected such that the electrode 2004 and balloon 2004 expand/deflate together. When the balloon 2002 is inflated, the electrode 2004 is expanded with the balloon 2002. When the balloon 2002 is deflated, the electrode 2004 contracts with the balloon 2002. The electrode 2004 may be coupled to an exterior surface or interior surface of the balloon 2002 and may be made of different types of conductive materials, including, without limitation, any chemically inert, non-toxic, structurally resilient, electrically conducting material. In some embodiments, the electrode 2004 is coupled to the exterior of the balloon 2002 and made, in whole or in part, of a highly conductive, deformable material. Energy outputted by the electrode 2004 is outputted directly into the airway wall 100 without passing through the wall of the balloon 2002. The electrode 2004 can be a thin wire or band made mostly or entirely of copper. The wire can be coated or uncoated depending on the application. In other embodiments, the electrode 2004 is embedded in the wall of the balloon 2002. Any number of electrodes 2004 can be positioned along the balloon 2002. For example, an array of spaced apart electrodes can be positioned along the balloon to treat a length of an airway.
The electrical conducting element 2031 travels along side and generally parallel to one or both of the lines 2011, 2021. The electrode 2004 can be connected through the electrical conducting element 2031 and the electrical connector 2038 to an energy source, such as an RF electrical generator. If the energy source is an RF electrical generator, one lead can be coupled to the connector 2038. The other lead of the RF generator may be connected to an external electrode, such as the external electrode 623 shown in phantom in
The balloon expandable, fluid cooled electrode catheter 2000 can be delivered into the airways of the lung with the balloon 2002 deflated and the electrode 2004 contracted. The electrode 2004 can be kept in a collapsed or closed configuration to allow the catheter 2000 to pass easily through the lungs. The catheter 2000 is moved through the airways until the electrode 2004 is at the desired treatment location. Once in position, fluid (e.g., coolant) is allowed to flow through the inflow line 2011 and into the balloon 2002. The fluid inflates the balloon 2002 which in turn expands the electrode 2004. Outflow of the fluid through the outflow line 2021 can be regulated such that the balloon 2002 continues to inflate until the electrode 2004 is brought into contact with or proximate to the airway wall.
Treatment can begin with activation of the RF generator. When the RF generator is activated, RF energy is transmitted through the electrical connector 2038, through the electrical connection element 2031, through the expanded electrode 2004, and into the tissues of the airways. The RF energy heats tissue (e.g., superficial and deep tissue) of the airway wall and the fluid 2100 (e.g., a coolant) flowing through the balloon 2002 cools tissue (e.g., superficial tissues) of the airway wall. The net effect of this superficial and deep heating by RF energy and superficial cooling by the circulating coolant 2100 through the balloon 2002 is the concentration of heat in the outer layers of the airway wall 100. The coolant can be a chilled liquid. The temperature of the connective tissue can be higher than the temperatures of the epithelium, stroma, and/or smooth muscle. By example, the temperature of the connective tissue can be sufficiently high to cause damage to the nerve trunk tissue while other non-targeted tissues of the airway are kept at a lower temperature to prevent or limit damage to the non-targeted tissues. In other embodiments, heat can be concentrated in one or more of the internal layers (e.g., the stroma) of the airway wall or in the inner lining (e.g., the epithelium) of the airway wall.
Curve A shown in
If active cooling is employed, the temperature drops to a much lower level, for example, about 35° C. as represented by the curve A1 at the electrode-tissue interface at 0 millimeters in distance. Since this temperature is below 50° C., cell death will not begin to occur until a distance of d2 at the point where the curve A2 crosses the cell death line at 50° C., for example, a depth of 3 millimeters from the surface. Cell death will occur at depths from 3 millimeters to 5 millimeters as represented by the distance d3. Such a cooled ablation procedure is advantageous because it permits cell death and tissue destruction to occur at a distance (or a range of distances) from the electrode-tissue interface without destroying the epithelium and the tissue immediately underlying the same. In some embodiments, the nerve tissues running along the outside of the airway can be ablated without damaging the epithelium or underlying structures, such as the stroma and smooth muscle cells.
The curve B represents what occurs with and without cooling of the electrode at a higher power level, for example, 20 watts of RF energy. Segment B2 of curve B represents a continuation of the exponential curve of the segment B3 without cooling. As can be seen, the temperature at the electrode-tissue interface approaches 100° C. which may be undesirable because that is a temperature at which boiling of tissue fluid and coagulation and charring of tissue at the tissue-electrode interface will occur, thus making significantly increasing the tissue impedance and compromising the ability to deliver additional RF energy into the airway wall. By providing active cooling, the curve B1 shows that the temperature at the electrode-tissue interface drops to approximately 40° C. and that cell death occurs at depths of two millimeters as represented by d4 to a depth of approximately 8 millimeters where the curve B3 crosses the 50° C. Thus, it can be seen that it is possible to provide a much deeper and larger region of cell death using the higher power level without reaching an undesirable high temperature (e.g., a temperature that would result in coagulation and charring of tissue at the electrode-tissue interface). The systems can be used to achieve cell death below the epithelia surface of the airway so that the surface need not be destroyed, thus facilitating early recovery by the patient from a treatment.
The curve C represents a still higher power level, for example, 40 watts of RF energy. The curve C includes segments C1, C2, and C3. The broken line segment C2 is a continuation of the exponential curve C3. Segment C2 shows that the temperature at the electrode-tissue interface far exceeds 100° C. and would be unsuitable without active cooling. With active cooling, the temperature at the electrode-tissue interface approaches 80° C. and gradually increases and approaches near 95° C. and then drops off exponentially to cross the 50° C. cell death line 2201 at a distance of about 15 millimeters from the electrode-tissue interface at the epithelial surface of the airway represented by the distance d6. Because the starting temperature is above the 50° C. cell death line 2201, tissue cell death will occur from the epithelial surface to a depth of about 15 millimeter to provide large and deep regions of tissue destruction.
The electrode catheter 2000 can treat tissue without forming an airway wall perforation at the treatment site to prevent or reduce the frequency of infections. It may also facilitate faster healing for the patient of tissue proximate the region of cell death. The catheter 2000 can produce relatively small regions of cell death. For example, a 2 to 3 millimeter band of tissue in the middle of the airway wall 100 or along the outer surface of the airway wall 100 can be destroyed. By the appropriate application of power and the appropriate removal of heat from the electrode, lesions can be created at any desired depth without damaging the inner surface of the airway.
Upon completion of the treatment process, coolant inflow into the balloon 2002 can be stopped. The balloon 2002 is deflated causing the expandable electrode 2004 to recoil away from the airway wall 100. When the balloon 2002 is completely deflated, the balloon expandable, fluid cooled electrode catheter 2000 may be repositioned for treating other locations in the lung or removed from the airway 100 entirely.
The balloon expandable, fluid heat-sink electrode catheter 2500 can be delivered into the airways of the lung with the balloon 2502 deflated and the electrode 2504 contracted. The catheter 2500 can be moved within the airways until the electrode 2504 is in a desired treatment location. Once in position, heat-sink fluid is passed through the line 2511 and into the balloon 2502, thereby inflating the balloon 2502 and expanding the electrode 2504. The fluid is passed into the balloon 2502 until the electrode 2504 is brought into contact with the airway wall 100.
The heat-sink fluid passed into the balloon 2502 of electrode catheter 2500 is generally static and acts as a heat-sink to stabilize the temperature of the electrode 2504 and the superficial tissues of the airway wall 100. The static heat sink provided by the fluid in the balloon 2502 can produce temperature profiles and isotherms similar to those shown in
The electrode catheter 3000 generally includes a distensible, thermally conductive balloon 3002, an electrode 3004, a conducting element 3031, an inflow line 3011, an outflow line 3021, and an ultrasound probe 3045. The expandable electrode 3004 is connected to a distal end of the conducting element 3031. A proximal end of the conducting element 3031 is connected to an electrical connector 3038 for transmission of energy (e.g., RF energy) to the electrode 3004. The proximal end of the coolant inflow line 3011 has an inline valve 3012. The proximal end of the coolant outflow line 3021 also has an outline valve 3022. The inflow valve 3012 can be connected to a coolant source by the connector 3018. The lumen of the inflow line 3011 and the lumen of the outflow line 3021 provide for fluid to flow from the fluid source to the inside of the balloon 3002 and for fluid flow through another connector 3028 to the coolant return, where the coolant may be re-cooled and re-circulated to the fluid supply.
The inflow line 3011 and outflow line 3021 have a suitable length to be passed into the lung and bronchial tree. For example, the catheter 3000 can have a length of approximately 80 cm.
The electrode 3004 is located on a surface of the balloon 3002 such that, when the balloon 3002 is inflated using fluid, the electrode 3004 is brought into contact with the airway wall 100. The electrical conducting element 3031 travels along side and parallel to the inflow line 3011, the outflow line 3021, and the ultrasound sheath 3041. The electrode 3004 can be connected through the electrical conducting element 3031 and the electrical connector 3038 to an RF generator. The other lead of the RF generator may be connected to an external electrode so that current flows between the expandable electrode 3004 and the external electrode.
The ultrasound probe 3045 may be an integral part of the ultrasound guided fluid cooled electrode catheter 3000 or it may be a separate, standard radial ultrasound probe, such as an Olympus UM-2R-3 or UM-3R-3 probe driven by a standard Olympus processor EU-M60, with the radial ultrasound guided fluid cooled electrode catheter 3000 configured to slip over the standard radial ultrasound probe.
The ultrasound system can include a broadband ultrasound transducer operating with a center frequency between about 7 MHz and about 50 MHz. If the ultrasound probe 3045 is an integral part of the electrode catheter 3000, the ultrasound probe 3045 may be contained within an acoustically matched ultrasound cover 3041 and connected to an ultrasound drive unit and processor by the ultrasound connector 3048. In operation, the ultrasound probe 3045 is rotated about its longitudinal axis within the ultrasound cover 3041 by the ultrasound drive unit and processor through the ultrasound connector 3048 allowing images (e.g., 360° radial images) to be taken. These images can be taken in a direction perpendicular to the long axis of the ultrasound probe 3045. The fluid in the balloon 3002 can acoustically couple the ultrasound probe 3045 to the airway wall.
The electrode catheter 3000 can be delivered into the airways of the lung with the balloon 3002 in a deflated state. The catheter 3000 is positioned within the airways near or at the desired treatment location. Once positioned, fluid flows through the inflow line 3011 and into the balloon 3002. The balloon 3002 inflates to bring the electrode 3004 into contact with the epithelial surface of the airway. Outflow of fluid through the outflow line 3021 can be regulated such that the balloon 3002 continues to inflate until the electrode 3004 is brought into contact with the airway wall 100.
The ultrasound drive unit and processor can be activated. The ultrasound probe 3045 can capture images. For example, the probe 3045, within the ultrasound cover 3041, can be rotated about its longitudinal axis to produce 360° radial images of the airway and vessels airway wall structures. The electrical connection wire 3031 can serve as a guide on the ultrasound images to the location of the electrode 3004. A section of the wire 3031 extending along (e.g., over the surface) of the balloon 3002 can be visible in the ultrasound images. The section of wire 3031 can therefore indicate the location of the electrode 3004. In some embodiments, the nerve trunks and bronchial blood can be identified in the ultrasound images and the ultrasound guided fluid cooled electrode catheter 3000 can be rotated until the electrode 3004 is brought into proximity with the first nerve trunk 45.
When the RF generator is activated, RF energy is transmitted by the generator through the electrical connector 3038, through the electrical connection wire 3031, through the expanded electrode 3004, and into the tissues of the airways. The RF energy heats the superficial and deep tissue of the airway wall 100 and the connective tissue 124 in the area immediately overlying the electrode 3004 and the coolant flowing 3100 through the balloon 3002 cools the superficial tissues of the airway wall 100. The net effect of this superficial and deep heating by RF energy and superficial cooling by the circulating coolant 3100 through the balloon 3002 is the concentration of heat in the outer layers of the airway wall 100 immediately overlying the electrode 3004. For example, the temperature of the connective tissue 124 in the area of a single nerve trunk 45 can be higher than the temperatures of the epithelium 110, stroma 112, and/or smooth muscle 114. By example, the temperature of the connective tissue can be sufficiently high to cause damage to the nerve tissue 45 while other non-targeted tissues of the airway 100 are kept at a lower temperature to prevent or limit damage to the non-targeted tissues. The treatment can be repeated in other areas as needed.
The balloon 3002 is conformable to both the electrode 3004 and the epithelial surface of the airway 100. When RF energy is transmitted through the electrode 3004 into the tissues of the airways and the balloon 3002 is filled with flowing coolant 3100, the RF energy heats the superficial and deep tissue of the airway wall 100 immediately overlying the electrode 3004. The coolant 3100 flows to control the temperature of the superficial tissues of the airway wall 100. The net effect is the concentration of heat in the outer layers of the airway wall 100 immediately over the electrode 3004 producing a single target volume 3250 of tissue heated above a treatment temperature (e.g., about 50° C.). For example, the temperature of the connective tissue 124 in the region of a single nerve trunk 45 in the region immediately over the electrode 3004 can be higher than the temperatures of the epithelium 110, stroma 112, and/or smooth muscle 114.
The vessels of the bronchial artery branches 130 may be within or near the volume of heating produced during application of RF energy. The heat generated by the electrode 3004 can be controlled such that blood flowing through the bronchial artery branches 130 protects those branches 130 from thermal injury while nerve tissue 45 is damaged, even if the nerve tissue is next to the artery branches.
The embodiments disclosed herein can be used in the respiratory system, digestive system, nervous system, vascular system, or other systems. For example, the elongate assemblies disclosed herein can be delivered through blood vessels to treat the vascular system. The treatment systems and its components disclosed herein can used as an adjunct during another medical procedure, such as minimally invasive procedures, open procedures, semi-open procedures, or other surgical procedures (e.g., lung volume reduction surgery) that preferably provide access to a desired target site. Various surgical procedures on the chest may provide access to lung tissue. Access techniques and procedures used to provide access to a target region can be performed by a surgeon and/or a robotic system. Those skilled in the art recognize that there are many different ways that a target region can be accessed.
The elongated assemblies disclosed herein can be used with guidewires, delivery sheaths, optical instruments, introducers, trocars, biopsy needles, or other suitable medical equipment. If the target treatment site is at a distant location in the patient (e.g., a treatment site near the lung root 24 of
Semi-rigid or rigid elongated assemblies can be delivered using trocars, access ports, rigid delivery sheaths using semi-open procedures, open procedures, or other delivery tools/procedures that provide a somewhat straight delivery path. Advantageously, the semi-rigid or rigid elongated assemblies can be sufficiently rigid to access and treat remote tissue, such as the vagus nerve, nerve branches, nerve fibers, and/or nerve trunks along the airways, without delivering the elongated assemblies through the airways. The embodiments and techniques disclosed herein can be used with other procedures, such as bronchial thermoplasty.
The various embodiments described above can be combined to provide further embodiments. These and other changes can be made to the embodiments in light of the above-detailed description. The embodiments, features, systems, devices, materials, methods and techniques described herein may, in some embodiments, be similar to any one or more of the embodiments, features, systems, devices, materials, methods and techniques described in of U.S. Provisional Patent Application No. 61/052,082 filed May 9, 2008; U.S. Provisional Patent Application No. 61/106,490 filed Oct. 17, 2008; and U.S. Provisional Patent Application No. 61/155,449 filed Feb. 25, 2009. In addition, the embodiments, features, systems, devices, materials, methods and techniques described herein may, in certain embodiments, be applied to or used in connection with any one or more of the embodiments, features, systems, devices, materials, methods and techniques disclosed in the above-mentioned of U.S. Provisional Patent Application No. 61/052,082 filed May 9, 2008; U.S. Provisional Patent Application No. 61/106,490 filed Oct. 17, 2008; and U.S. Provisional Patent Application No. 61/155,449 filed Feb. 25, 2009. Each of these applications is hereby incorporated by reference in its entirety. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
This application is a continuation of U.S. patent application Ser. No. 13/452,664, now U.S. Pat. No. 8,808,280, filed Apr. 20, 2012, which is a continuation of U.S. patent application Ser. No. 13/245,522, now U.S. Pat. No. 8,226,638, filed Sep. 26, 2011, which is a continuation of U.S. patent application Ser. No. 12/463,304, now U.S. Pat. No. 8,088,127, filed May 8, 2009, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 61/052,082 filed May 9, 2008; U.S. Provisional Patent Application No. 61/106,490 filed Oct. 17, 2008; and U.S. Provisional Patent Application No. 61/155,449 filed Feb. 25, 2009. Each of these applications is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 612724 | Hamilton | Oct 1898 | A |
| 1155169 | Starkweather | Sep 1915 | A |
| 1207479 | Bisgaard | Dec 1916 | A |
| 1216183 | Swingle | Feb 1917 | A |
| 1695107 | Kahl | Dec 1928 | A |
| 2072346 | Smith | Mar 1937 | A |
| 2279714 | Meyerhof et al. | Apr 1942 | A |
| 3320957 | Sokolik | May 1967 | A |
| 3568659 | Karnegis | Mar 1971 | A |
| 3667476 | Muller | Jun 1972 | A |
| 3692029 | Adair | Sep 1972 | A |
| 3918449 | Pistor | Nov 1975 | A |
| 3946745 | Hsiang-Lai et al. | Mar 1976 | A |
| 3949743 | Shanbrom | Apr 1976 | A |
| 3995617 | Watkins et al. | Dec 1976 | A |
| 4078864 | Howell | Mar 1978 | A |
| 4095602 | Leveen | Jun 1978 | A |
| 4116589 | Rishton | Sep 1978 | A |
| 4129129 | Amrine | Dec 1978 | A |
| 4154246 | LeVeen | May 1979 | A |
| 4277168 | Oku | Jul 1981 | A |
| 4305402 | Katims | Dec 1981 | A |
| 4351330 | Scarberry | Sep 1982 | A |
| 4461283 | Doi | Jul 1984 | A |
| 4502490 | Evans et al. | Mar 1985 | A |
| 4503855 | Maslanka | Mar 1985 | A |
| 4503863 | Katims | Mar 1985 | A |
| 4512762 | Spears | Apr 1985 | A |
| 4522212 | Gelinas et al. | Jun 1985 | A |
| 4557272 | Carr | Dec 1985 | A |
| 4565200 | Cosman | Jan 1986 | A |
| 4567882 | Heller | Feb 1986 | A |
| 4573481 | Bullara | Mar 1986 | A |
| 4584998 | McGrail | Apr 1986 | A |
| 4612934 | Borkan | Sep 1986 | A |
| 4621642 | Chen | Nov 1986 | A |
| 4621882 | Krumme | Nov 1986 | A |
| 4625712 | Wampler | Dec 1986 | A |
| 4643186 | Rosen et al. | Feb 1987 | A |
| 4646737 | Hussein et al. | Mar 1987 | A |
| 4649924 | Taccardi | Mar 1987 | A |
| 4649935 | Charmillot et al. | Mar 1987 | A |
| 4658836 | Turner | Apr 1987 | A |
| 4674497 | Ogasawara | Jun 1987 | A |
| 4683890 | Hewson | Aug 1987 | A |
| 4704121 | Moise | Nov 1987 | A |
| 4706688 | Don Michael et al. | Nov 1987 | A |
| 4709698 | Johnston et al. | Dec 1987 | A |
| 4739759 | Rexroth et al. | Apr 1988 | A |
| 4754065 | Levenson et al. | Jun 1988 | A |
| 4754752 | Ginsburg et al. | Jul 1988 | A |
| 4765322 | Charmillot et al. | Aug 1988 | A |
| 4765959 | Fukasawa | Aug 1988 | A |
| 4767402 | Kost et al. | Aug 1988 | A |
| 4772112 | Zider et al. | Sep 1988 | A |
| 4773899 | Spears | Sep 1988 | A |
| 4779614 | Moise | Oct 1988 | A |
| 4784135 | Blum et al. | Nov 1988 | A |
| 4790305 | Zoltan et al. | Dec 1988 | A |
| 4799479 | Spears | Jan 1989 | A |
| 4802492 | Grunstein | Feb 1989 | A |
| 4808164 | Hess | Feb 1989 | A |
| 4817586 | Wampler | Apr 1989 | A |
| 4825871 | Cans Ell | May 1989 | A |
| 4827935 | Geddes et al. | May 1989 | A |
| 4846152 | Wampler et al. | Jul 1989 | A |
| 4862886 | Clarke et al. | Sep 1989 | A |
| 4881542 | Schmidt et al. | Nov 1989 | A |
| 4895557 | Moise et al. | Jan 1990 | A |
| 4902129 | Siegmund et al. | Feb 1990 | A |
| 4904472 | Belardinelli et al. | Feb 1990 | A |
| 4906229 | Wampler | Mar 1990 | A |
| 4907589 | Cosman | Mar 1990 | A |
| 4908012 | Moise et al. | Mar 1990 | A |
| 4920978 | Colvin | May 1990 | A |
| 4944722 | Carriker et al. | Jul 1990 | A |
| 4945910 | Budyko et al. | Aug 1990 | A |
| 4955377 | Lennox et al. | Sep 1990 | A |
| 4967765 | Turner et al. | Nov 1990 | A |
| 4969865 | Hwang et al. | Nov 1990 | A |
| 4976709 | Sand | Dec 1990 | A |
| 4985014 | Orejola | Jan 1991 | A |
| 4989604 | Fang | Feb 1991 | A |
| 4991603 | Cohen et al. | Feb 1991 | A |
| 4992474 | Skidmore et al. | Feb 1991 | A |
| 5005559 | Blanco et al. | Apr 1991 | A |
| 5007908 | Rydell | Apr 1991 | A |
| 5009636 | Wortley et al. | Apr 1991 | A |
| 5009936 | Yamanaka et al. | Apr 1991 | A |
| 5010892 | Colvin et al. | Apr 1991 | A |
| 5019075 | Spears et al. | May 1991 | A |
| 5027829 | Larsen | Jul 1991 | A |
| 5030645 | Kollonitsch | Jul 1991 | A |
| 5036848 | Hewson | Aug 1991 | A |
| 5053033 | Clarke | Oct 1991 | A |
| 5054486 | Yamada | Oct 1991 | A |
| 5056519 | Vince | Oct 1991 | A |
| 5056529 | de Groot | Oct 1991 | A |
| 5057107 | Parins et al. | Oct 1991 | A |
| 5074860 | Gregory et al. | Dec 1991 | A |
| 5078716 | Doll | Jan 1992 | A |
| 5084044 | Quint | Jan 1992 | A |
| 5096916 | Skupin | Mar 1992 | A |
| 5100388 | Behl et al. | Mar 1992 | A |
| 5100423 | Fearnot | Mar 1992 | A |
| 5103804 | Abele et al. | Apr 1992 | A |
| 5105826 | Smits et al. | Apr 1992 | A |
| 5106360 | Ishiwara et al. | Apr 1992 | A |
| 5107830 | Younes | Apr 1992 | A |
| 5107835 | Thomas | Apr 1992 | A |
| 5109846 | Thomas | May 1992 | A |
| 5114423 | Kasprzyk et al. | May 1992 | A |
| 5116864 | March et al. | May 1992 | A |
| 5117828 | Metzger et al. | Jun 1992 | A |
| 5123413 | Hasegawa et al. | Jun 1992 | A |
| 5126375 | Skidmore et al. | Jun 1992 | A |
| 5135480 | Bannon et al. | Aug 1992 | A |
| 5135517 | McCoy | Aug 1992 | A |
| 5139029 | Fishman et al. | Aug 1992 | A |
| 5151100 | Abele et al. | Sep 1992 | A |
| 5152286 | Sitko et al. | Oct 1992 | A |
| 5165420 | Strickland | Nov 1992 | A |
| 5167223 | Koros et al. | Dec 1992 | A |
| 5170802 | Mehra | Dec 1992 | A |
| 5170803 | Hewson et al. | Dec 1992 | A |
| 5174288 | Bardy et al. | Dec 1992 | A |
| 5188602 | Nichols | Feb 1993 | A |
| 5190540 | Lee | Mar 1993 | A |
| 5191883 | Lennox et al. | Mar 1993 | A |
| 5213576 | Abiuso et al. | May 1993 | A |
| 5215103 | Desai | Jun 1993 | A |
| 5224491 | Mehra | Jul 1993 | A |
| 5225445 | Skidmore et al. | Jul 1993 | A |
| 5231996 | Bardy et al. | Aug 1993 | A |
| 5232444 | Just et al. | Aug 1993 | A |
| 5234456 | Silvestrini | Aug 1993 | A |
| 5239982 | Trauthen | Aug 1993 | A |
| 5254088 | Lundquist et al. | Oct 1993 | A |
| 5255678 | Deslauriers et al. | Oct 1993 | A |
| 5255679 | Imran | Oct 1993 | A |
| 5265604 | Vince | Nov 1993 | A |
| 5269758 | Taheri | Dec 1993 | A |
| 5281218 | Imran | Jan 1994 | A |
| 5286254 | Shapland et al. | Feb 1994 | A |
| 5292331 | Boneau | Mar 1994 | A |
| 5293869 | Edwards et al. | Mar 1994 | A |
| 5309910 | Edwards et al. | May 1994 | A |
| 5311866 | Kagan et al. | May 1994 | A |
| 5313943 | Houser et al. | May 1994 | A |
| 5324255 | Passafaro et al. | Jun 1994 | A |
| 5324284 | Imran | Jun 1994 | A |
| 5343936 | Beatenbough et al. | Sep 1994 | A |
| 5344398 | Hara | Sep 1994 | A |
| 5345936 | Pomeranz et al. | Sep 1994 | A |
| 5348554 | Imran et al. | Sep 1994 | A |
| 5366443 | Eggers et al. | Nov 1994 | A |
| 5368591 | Lennox et al. | Nov 1994 | A |
| 5370644 | Langberg | Dec 1994 | A |
| 5370675 | Edwards et al. | Dec 1994 | A |
| 5370679 | Atlee, III | Dec 1994 | A |
| 5372603 | Acker et al. | Dec 1994 | A |
| 5374287 | Rubin | Dec 1994 | A |
| 5379765 | Kajiwara et al. | Jan 1995 | A |
| 5383917 | Desai et al. | Jan 1995 | A |
| 5393207 | Maher et al. | Feb 1995 | A |
| 5394880 | Atlee, III | Mar 1995 | A |
| 5396887 | Imran | Mar 1995 | A |
| 5400778 | Jonson et al. | Mar 1995 | A |
| 5400783 | Pomeranz et al. | Mar 1995 | A |
| 5405362 | Kramer et al. | Apr 1995 | A |
| 5405366 | Fox et al. | Apr 1995 | A |
| 5411025 | Webster, Jr. | May 1995 | A |
| 5415166 | Imran | May 1995 | A |
| 5415656 | Tihon et al. | May 1995 | A |
| 5417687 | Nardella et al. | May 1995 | A |
| 5422362 | Vincent et al. | Jun 1995 | A |
| 5423744 | Gencheff et al. | Jun 1995 | A |
| 5423811 | Imran et al. | Jun 1995 | A |
| 5425023 | Haraguchi et al. | Jun 1995 | A |
| 5425703 | Feiring | Jun 1995 | A |
| 5425811 | Mashita | Jun 1995 | A |
| 5431696 | Atlee, III | Jul 1995 | A |
| 5433730 | Alt | Jul 1995 | A |
| 5437665 | Munro | Aug 1995 | A |
| 5443470 | Stern et al. | Aug 1995 | A |
| 5454782 | Perkins | Oct 1995 | A |
| 5454840 | Krakovsky et al. | Oct 1995 | A |
| 5456667 | Ham et al. | Oct 1995 | A |
| 5458596 | Lax et al. | Oct 1995 | A |
| 5465717 | Imran et al. | Nov 1995 | A |
| 5470352 | Rappaport | Nov 1995 | A |
| 5471982 | Edwards et al. | Dec 1995 | A |
| 5474530 | Passafaro et al. | Dec 1995 | A |
| 5478309 | Sweezer et al. | Dec 1995 | A |
| 5478578 | Arnold et al. | Dec 1995 | A |
| 5496271 | Burton et al. | Mar 1996 | A |
| 5496304 | Chasan | Mar 1996 | A |
| 5496311 | Abele et al. | Mar 1996 | A |
| 5496312 | Klicek | Mar 1996 | A |
| 5500011 | Desai | Mar 1996 | A |
| 5505728 | Ellman et al. | Apr 1996 | A |
| 5505730 | Edwards | Apr 1996 | A |
| 5507791 | Sitko | Apr 1996 | A |
| 5509419 | Edwards et al. | Apr 1996 | A |
| 5522862 | Testerman et al. | Jun 1996 | A |
| 5531779 | Dahl et al. | Jul 1996 | A |
| 5540681 | Strul et al. | Jul 1996 | A |
| 5540730 | Terry, Jr. et al. | Jul 1996 | A |
| 5545161 | Imran | Aug 1996 | A |
| 5545193 | Fleischman et al. | Aug 1996 | A |
| 5547469 | Rowland et al. | Aug 1996 | A |
| 5549559 | Eshel | Aug 1996 | A |
| 5549655 | Erickson | Aug 1996 | A |
| 5549661 | Kordis et al. | Aug 1996 | A |
| RE35330 | Malone et al. | Sep 1996 | E |
| 5553611 | Budd et al. | Sep 1996 | A |
| 5558073 | Pomeranz et al. | Sep 1996 | A |
| 5562608 | Sekins et al. | Oct 1996 | A |
| 5571074 | Buckman, Jr. et al. | Nov 1996 | A |
| 5571088 | Lennox et al. | Nov 1996 | A |
| 5574059 | Regunathan et al. | Nov 1996 | A |
| 5578072 | Barone et al. | Nov 1996 | A |
| 5582609 | Swanson et al. | Dec 1996 | A |
| 5588432 | Crowley | Dec 1996 | A |
| 5588812 | Taylor et al. | Dec 1996 | A |
| 5595183 | Swanson et al. | Jan 1997 | A |
| 5598848 | Swanson et al. | Feb 1997 | A |
| 5599345 | Edwards et al. | Feb 1997 | A |
| 5601088 | Swanson et al. | Feb 1997 | A |
| 5605157 | Panescu et al. | Feb 1997 | A |
| 5607419 | Amplatz et al. | Mar 1997 | A |
| 5607462 | Imran | Mar 1997 | A |
| 5620438 | Amplatz et al. | Apr 1997 | A |
| 5620463 | Drolet | Apr 1997 | A |
| 5623940 | Daikuzono | Apr 1997 | A |
| 5624392 | Saab | Apr 1997 | A |
| 5624439 | Edwards et al. | Apr 1997 | A |
| 5626618 | Ward et al. | May 1997 | A |
| 5630425 | Panescu et al. | May 1997 | A |
| 5630794 | Lax et al. | May 1997 | A |
| 5630813 | Kieturakis | May 1997 | A |
| 5634471 | Fairfax et al. | Jun 1997 | A |
| 5641326 | Adams | Jun 1997 | A |
| 5647870 | Kordis et al. | Jul 1997 | A |
| 5658278 | Imran et al. | Aug 1997 | A |
| 5658322 | Fleming | Aug 1997 | A |
| 5658549 | Akehurst et al. | Aug 1997 | A |
| 5660175 | Dayal | Aug 1997 | A |
| 5662108 | Budd et al. | Sep 1997 | A |
| 5669930 | Igarashi | Sep 1997 | A |
| 5669932 | Fischell et al. | Sep 1997 | A |
| 5674472 | Akehurst et al. | Oct 1997 | A |
| 5678535 | DiMarco | Oct 1997 | A |
| 5680860 | Imran | Oct 1997 | A |
| 5681280 | Rusk et al. | Oct 1997 | A |
| 5681308 | Edwards et al. | Oct 1997 | A |
| 5687723 | Avitall | Nov 1997 | A |
| 5688267 | Panescu et al. | Nov 1997 | A |
| 5690692 | Fleming | Nov 1997 | A |
| 5693078 | Desaj et al. | Dec 1997 | A |
| 5694934 | Edelman | Dec 1997 | A |
| 5695471 | Wampler | Dec 1997 | A |
| 5699799 | Xu et al. | Dec 1997 | A |
| 5702386 | Stern et al. | Dec 1997 | A |
| 5707218 | Maher et al. | Jan 1998 | A |
| 5707336 | Rubin | Jan 1998 | A |
| 5707352 | Sekins et al. | Jan 1998 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5722401 | Pietroski et al. | Mar 1998 | A |
| 5722403 | McGee et al. | Mar 1998 | A |
| 5722416 | Swanson et al. | Mar 1998 | A |
| 5725525 | Kordis | Mar 1998 | A |
| 5727569 | Benetti et al. | Mar 1998 | A |
| 5728094 | Edwards | Mar 1998 | A |
| 5730128 | Pomeranz et al. | Mar 1998 | A |
| 5730704 | Avitall | Mar 1998 | A |
| 5730726 | Klingenstein | Mar 1998 | A |
| 5730741 | Horzewski et al. | Mar 1998 | A |
| 5733319 | Neilson et al. | Mar 1998 | A |
| 5735846 | Panescu et al. | Apr 1998 | A |
| 5740808 | Panescu et al. | Apr 1998 | A |
| 5741248 | Stern et al. | Apr 1998 | A |
| 5746224 | Edwards | May 1998 | A |
| 5752518 | McGee et al. | May 1998 | A |
| 5755714 | Murphy-Chutorian | May 1998 | A |
| 5755753 | Knowlton | May 1998 | A |
| 5759158 | Swanson | Jun 1998 | A |
| 5765568 | Sweezer, Jr. et al. | Jun 1998 | A |
| 5766605 | Sanders et al. | Jun 1998 | A |
| 5769846 | Edwards et al. | Jun 1998 | A |
| 5772590 | Webster, Jr. | Jun 1998 | A |
| 5779669 | Haissaguerre et al. | Jul 1998 | A |
| 5779698 | Clayman et al. | Jul 1998 | A |
| 5782239 | Webster, Jr. | Jul 1998 | A |
| 5782797 | Schweich, Jr. et al. | Jul 1998 | A |
| 5782827 | Gough et al. | Jul 1998 | A |
| 5782848 | Lennox | Jul 1998 | A |
| 5782899 | Imran | Jul 1998 | A |
| 5792064 | Panescu et al. | Aug 1998 | A |
| 5795303 | Swanson et al. | Aug 1998 | A |
| 5800375 | Sweezer et al. | Sep 1998 | A |
| 5800486 | Thome et al. | Sep 1998 | A |
| 5807306 | Shapland et al. | Sep 1998 | A |
| 5810757 | Sweezer, Jr. et al. | Sep 1998 | A |
| 5810807 | Ganz et al. | Sep 1998 | A |
| 5814078 | Zhou et al. | Sep 1998 | A |
| 5817028 | Anderson | Oct 1998 | A |
| 5817073 | Krespi | Oct 1998 | A |
| 5820554 | Davis et al. | Oct 1998 | A |
| 5820589 | Torgerson et al. | Oct 1998 | A |
| 5823189 | Kordis | Oct 1998 | A |
| 5827277 | Edwards | Oct 1998 | A |
| 5833651 | Donovan et al. | Nov 1998 | A |
| 5836874 | Swanson et al. | Nov 1998 | A |
| 5836905 | Lemelson et al. | Nov 1998 | A |
| 5836947 | Fleischman et al. | Nov 1998 | A |
| 5837001 | Mackey | Nov 1998 | A |
| 5843075 | Taylor | Dec 1998 | A |
| 5843077 | Edwards | Dec 1998 | A |
| 5843088 | Barra et al. | Dec 1998 | A |
| 5846238 | Jackson et al. | Dec 1998 | A |
| 5848969 | Panescu et al. | Dec 1998 | A |
| 5848972 | Triedman et al. | Dec 1998 | A |
| 5849026 | Zhou et al. | Dec 1998 | A |
| 5855577 | Murphy-Chutorian et al. | Jan 1999 | A |
| 5860974 | Abele | Jan 1999 | A |
| 5863291 | Schaer | Jan 1999 | A |
| 5865791 | Whayne et al. | Feb 1999 | A |
| 5868740 | LeVeen et al. | Feb 1999 | A |
| 5871443 | Edwards et al. | Feb 1999 | A |
| 5871483 | Jackson et al. | Feb 1999 | A |
| 5871523 | Fleischman et al. | Feb 1999 | A |
| 5873852 | Vigil et al. | Feb 1999 | A |
| 5873865 | Horzewski et al. | Feb 1999 | A |
| 5876340 | Tu et al. | Mar 1999 | A |
| 5876399 | Chia et al. | Mar 1999 | A |
| 5881727 | Edwards | Mar 1999 | A |
| 5882346 | Pomeranz et al. | Mar 1999 | A |
| 5891027 | Tu et al. | Apr 1999 | A |
| 5891135 | Jackson et al. | Apr 1999 | A |
| 5891136 | McGee et al. | Apr 1999 | A |
| 5891138 | Tu et al. | Apr 1999 | A |
| 5891182 | Fleming | Apr 1999 | A |
| 5893847 | Kordis | Apr 1999 | A |
| 5893887 | Jayaraman | Apr 1999 | A |
| 5897554 | Chia et al. | Apr 1999 | A |
| 5899882 | Waksman et al. | May 1999 | A |
| 5902268 | Saab | May 1999 | A |
| 5904651 | Swanson et al. | May 1999 | A |
| 5904711 | Flom et al. | May 1999 | A |
| 5906636 | Casscells, III et al. | May 1999 | A |
| 5908445 | Whayne et al. | Jun 1999 | A |
| 5908446 | Imran | Jun 1999 | A |
| 5908839 | Levitt et al. | Jun 1999 | A |
| 5911218 | DiMarco | Jun 1999 | A |
| 5916235 | Guglielmi | Jun 1999 | A |
| 5919147 | Jain | Jul 1999 | A |
| 5919172 | Golba, Jr. | Jul 1999 | A |
| 5924424 | Stevens et al. | Jul 1999 | A |
| 5928228 | Kordis et al. | Jul 1999 | A |
| 5931806 | Shimada | Aug 1999 | A |
| 5931835 | Mackey | Aug 1999 | A |
| 5935079 | Swanson et al. | Aug 1999 | A |
| 5941869 | Patterson et al. | Aug 1999 | A |
| 5951494 | Wang et al. | Sep 1999 | A |
| 5951546 | Lorentzen | Sep 1999 | A |
| 5954661 | Greenspon et al. | Sep 1999 | A |
| 5954662 | Swanson et al. | Sep 1999 | A |
| 5954717 | Behl et al. | Sep 1999 | A |
| 5956501 | Brown | Sep 1999 | A |
| 5957919 | Laufer | Sep 1999 | A |
| 5957961 | Maguire et al. | Sep 1999 | A |
| 5964223 | Baran | Oct 1999 | A |
| 5964753 | Edwards | Oct 1999 | A |
| 5964796 | Imran | Oct 1999 | A |
| 5971983 | Lesh | Oct 1999 | A |
| 5972026 | Laufer et al. | Oct 1999 | A |
| 5976175 | Hirano et al. | Nov 1999 | A |
| 5976709 | Kageyama et al. | Nov 1999 | A |
| 5979456 | Magovern | Nov 1999 | A |
| 5980563 | Tu et al. | Nov 1999 | A |
| 5984917 | Fleischman et al. | Nov 1999 | A |
| 5984971 | Faccioli et al. | Nov 1999 | A |
| 5989545 | Foster et al. | Nov 1999 | A |
| 5991650 | Swanson et al. | Nov 1999 | A |
| 5992419 | Sterzer et al. | Nov 1999 | A |
| 5993462 | Pomeranz et al. | Nov 1999 | A |
| 5995873 | Rhodes | Nov 1999 | A |
| 5997534 | Tu et al. | Dec 1999 | A |
| 5999855 | DiMarco | Dec 1999 | A |
| 6001054 | Regulla et al. | Dec 1999 | A |
| 6003517 | Sheffield et al. | Dec 1999 | A |
| 6004269 | Crowley et al. | Dec 1999 | A |
| 6006134 | Hill et al. | Dec 1999 | A |
| 6006755 | Edwards | Dec 1999 | A |
| 6008211 | Robinson et al. | Dec 1999 | A |
| 6009877 | Edwards | Jan 2000 | A |
| 6010500 | Sherman et al. | Jan 2000 | A |
| 6012457 | Lesh | Jan 2000 | A |
| 6014579 | Pomeranz et al. | Jan 2000 | A |
| 6016437 | Tu et al. | Jan 2000 | A |
| 6023638 | Swanson | Feb 2000 | A |
| 6024740 | Lesh et al. | Feb 2000 | A |
| 6029091 | de la Rama et al. | Feb 2000 | A |
| 6033397 | Laufer et al. | Mar 2000 | A |
| 6036687 | Laufer et al. | Mar 2000 | A |
| 6036689 | Tu et al. | Mar 2000 | A |
| 6039731 | Taylor et al. | Mar 2000 | A |
| 6043273 | Duhaylongsod | Mar 2000 | A |
| 6045549 | Smethers et al. | Apr 2000 | A |
| 6045550 | Simpson et al. | Apr 2000 | A |
| 6050992 | Nichols | Apr 2000 | A |
| 6052607 | Edwards et al. | Apr 2000 | A |
| 6053172 | Hovda et al. | Apr 2000 | A |
| 6053909 | Shadduck | Apr 2000 | A |
| 6056744 | Edwards | May 2000 | A |
| 6056745 | Panescu et al. | May 2000 | A |
| 6056769 | Epstein et al. | May 2000 | A |
| 6060454 | Duhaylongsod | May 2000 | A |
| 6063078 | Wittkampf | May 2000 | A |
| 6063768 | First | May 2000 | A |
| 6071280 | Edwards et al. | Jun 2000 | A |
| 6071281 | Burnside et al. | Jun 2000 | A |
| 6071282 | Fleischman | Jun 2000 | A |
| 6081749 | Ingle et al. | Jun 2000 | A |
| 6083249 | Familoni | Jul 2000 | A |
| 6083255 | Laufer et al. | Jul 2000 | A |
| 6087394 | Duhaylongsod | Jul 2000 | A |
| 6090104 | Webster, Jr. | Jul 2000 | A |
| 6091995 | Ingle et al. | Jul 2000 | A |
| 6092528 | Edwards | Jul 2000 | A |
| 6097985 | Kasevich et al. | Aug 2000 | A |
| 6101412 | Duhaylongsod | Aug 2000 | A |
| 6102886 | Lundquist et al. | Aug 2000 | A |
| 6106524 | Eggers et al. | Aug 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6123702 | Swanson et al. | Sep 2000 | A |
| 6123703 | Tu et al. | Sep 2000 | A |
| 6123718 | Tu et al. | Sep 2000 | A |
| 6125301 | Capel | Sep 2000 | A |
| 6127410 | Duhaylongsod | Oct 2000 | A |
| 6129726 | Edwards et al. | Oct 2000 | A |
| 6135997 | Laufer et al. | Oct 2000 | A |
| 6139527 | Laufer et al. | Oct 2000 | A |
| 6139571 | Fuller et al. | Oct 2000 | A |
| 6139845 | Donovan | Oct 2000 | A |
| 6141589 | Duhaylongsod | Oct 2000 | A |
| 6142993 | Whayne et al. | Nov 2000 | A |
| 6143013 | Samson et al. | Nov 2000 | A |
| 6143277 | Ashurst et al. | Nov 2000 | A |
| 6149647 | Tu et al. | Nov 2000 | A |
| 6152143 | Edwards | Nov 2000 | A |
| 6152899 | Farley et al. | Nov 2000 | A |
| 6152953 | Hipskind | Nov 2000 | A |
| 6159194 | Eggers et al. | Dec 2000 | A |
| 6163716 | Edwards et al. | Dec 2000 | A |
| 6174323 | Biggs et al. | Jan 2001 | B1 |
| 6179833 | Taylor | Jan 2001 | B1 |
| 6183468 | Swanson et al. | Feb 2001 | B1 |
| 6197013 | Reed et al. | Mar 2001 | B1 |
| 6198970 | Freed et al. | Mar 2001 | B1 |
| 6200311 | Danek et al. | Mar 2001 | B1 |
| 6200332 | Del Giglio | Mar 2001 | B1 |
| 6200333 | Laufer | Mar 2001 | B1 |
| 6203562 | Ohkubo | Mar 2001 | B1 |
| 6210355 | Edwards et al. | Apr 2001 | B1 |
| 6210367 | Carr | Apr 2001 | B1 |
| 6212432 | Matsuura | Apr 2001 | B1 |
| 6212433 | Behl | Apr 2001 | B1 |
| 6214002 | Fleischman et al. | Apr 2001 | B1 |
| 6216043 | Swanson et al. | Apr 2001 | B1 |
| 6216044 | Kordis | Apr 2001 | B1 |
| 6216704 | Ingle et al. | Apr 2001 | B1 |
| 6217576 | Tu et al. | Apr 2001 | B1 |
| 6226543 | Gilboa et al. | May 2001 | B1 |
| 6230052 | Wolff et al. | May 2001 | B1 |
| 6231595 | Dobak, III | May 2001 | B1 |
| 6235024 | Tu | May 2001 | B1 |
| 6240307 | Beatty et al. | May 2001 | B1 |
| 6241727 | Tu et al. | Jun 2001 | B1 |
| 6245040 | Inderbitzen et al. | Jun 2001 | B1 |
| 6245065 | Panescu et al. | Jun 2001 | B1 |
| 6251368 | Akehurst et al. | Jun 2001 | B1 |
| 6253762 | Britto | Jul 2001 | B1 |
| 6254598 | Edwards et al. | Jul 2001 | B1 |
| 6254599 | Lesh et al. | Jul 2001 | B1 |
| 6258083 | Daniel et al. | Jul 2001 | B1 |
| 6258087 | Edwards et al. | Jul 2001 | B1 |
| 6264653 | Falwell | Jul 2001 | B1 |
| 6265379 | Donovan | Jul 2001 | B1 |
| 6269813 | Fitzgerald et al. | Aug 2001 | B1 |
| 6270476 | Santoianni et al. | Aug 2001 | B1 |
| 6273886 | Edwards et al. | Aug 2001 | B1 |
| 6273907 | Laufer | Aug 2001 | B1 |
| 6283987 | Laird et al. | Sep 2001 | B1 |
| 6283988 | Laufer et al. | Sep 2001 | B1 |
| 6283989 | Laufer et al. | Sep 2001 | B1 |
| 6287304 | Eggers et al. | Sep 2001 | B1 |
| 6296639 | Truckai et al. | Oct 2001 | B1 |
| 6299633 | Laufer | Oct 2001 | B1 |
| 6302870 | Jacobsen et al. | Oct 2001 | B1 |
| 6303509 | Chen et al. | Oct 2001 | B1 |
| 6306423 | Donovan et al. | Oct 2001 | B1 |
| 6315173 | Di Giovanni et al. | Nov 2001 | B1 |
| 6315778 | Gambale et al. | Nov 2001 | B1 |
| 6317615 | KenKnight et al. | Nov 2001 | B1 |
| 6322559 | Daulton et al. | Nov 2001 | B1 |
| 6322584 | Ingle et al. | Nov 2001 | B2 |
| 6325798 | Edwards et al. | Dec 2001 | B1 |
| 6327503 | Familoni | Dec 2001 | B1 |
| 6338727 | Noda et al. | Jan 2002 | B1 |
| 6338836 | Kuth et al. | Jan 2002 | B1 |
| 6341236 | Osorio et al. | Jan 2002 | B1 |
| 6346104 | Daly et al. | Feb 2002 | B2 |
| 6355031 | Edwards et al. | Mar 2002 | B1 |
| 6356786 | Rezai et al. | Mar 2002 | B1 |
| 6356787 | Rezai et al. | Mar 2002 | B1 |
| 6357447 | Swanson et al. | Mar 2002 | B1 |
| 6358245 | Edwards et al. | Mar 2002 | B1 |
| 6358926 | Donovan | Mar 2002 | B2 |
| 6361554 | Brisken | Mar 2002 | B1 |
| 6363937 | Hovda et al. | Apr 2002 | B1 |
| 6366814 | Boveja et al. | Apr 2002 | B1 |
| 6379352 | Reynolds et al. | Apr 2002 | B1 |
| 6383509 | Donovan et al. | May 2002 | B1 |
| 6394956 | Chandrasekaran et al. | May 2002 | B1 |
| 6402744 | Edwards et al. | Jun 2002 | B2 |
| 6405732 | Edwards et al. | Jun 2002 | B1 |
| 6409723 | Edwards | Jun 2002 | B1 |
| 6411852 | Danek et al. | Jun 2002 | B1 |
| 6414018 | Duhaylongsod | Jul 2002 | B1 |
| 6416511 | Lesh et al. | Jul 2002 | B1 |
| 6416740 | Unger | Jul 2002 | B1 |
| 6423058 | Edwards et al. | Jul 2002 | B1 |
| 6423105 | Iijima et al. | Jul 2002 | B1 |
| 6424864 | Matsuura | Jul 2002 | B1 |
| 6425877 | Edwards | Jul 2002 | B1 |
| 6425887 | McGuckin et al. | Jul 2002 | B1 |
| 6425895 | Swanson et al. | Jul 2002 | B1 |
| 6432092 | Miller | Aug 2002 | B2 |
| 6436130 | Philips et al. | Aug 2002 | B1 |
| 6438423 | Rezai et al. | Aug 2002 | B1 |
| 6440128 | Edwards et al. | Aug 2002 | B1 |
| 6440129 | Simpson | Aug 2002 | B1 |
| 6442435 | King et al. | Aug 2002 | B2 |
| 6447505 | McGovern et al. | Sep 2002 | B2 |
| 6447785 | Donovan | Sep 2002 | B1 |
| 6448231 | Graham | Sep 2002 | B2 |
| 6451013 | Bays et al. | Sep 2002 | B1 |
| 6458121 | Rosenstock et al. | Oct 2002 | B1 |
| 6460545 | Kordis | Oct 2002 | B2 |
| 6464680 | Brisken et al. | Oct 2002 | B1 |
| 6464697 | Edwards et al. | Oct 2002 | B1 |
| 6475160 | Sher | Nov 2002 | B1 |
| 6480746 | Ingle et al. | Nov 2002 | B1 |
| 6485416 | Platt et al. | Nov 2002 | B1 |
| 6488673 | Laufer | Dec 2002 | B1 |
| 6488679 | Swanson et al. | Dec 2002 | B1 |
| 6491710 | Satake | Dec 2002 | B2 |
| 6493589 | Medhkour et al. | Dec 2002 | B1 |
| 6494880 | Swanson et al. | Dec 2002 | B1 |
| 6496737 | Rudie et al. | Dec 2002 | B2 |
| 6496738 | Carr | Dec 2002 | B2 |
| 6506399 | Donovan | Jan 2003 | B2 |
| 6510969 | Di Giovanni et al. | Jan 2003 | B2 |
| 6514246 | Swanson et al. | Feb 2003 | B1 |
| 6514290 | Loomas | Feb 2003 | B1 |
| 6519488 | KenKnight et al. | Feb 2003 | B2 |
| 6522913 | Swanson et al. | Feb 2003 | B2 |
| 6524555 | Ashurst et al. | Feb 2003 | B1 |
| 6526320 | Mitchell | Feb 2003 | B2 |
| 6526976 | Baran | Mar 2003 | B1 |
| 6529756 | Phan et al. | Mar 2003 | B1 |
| 6532388 | Hill et al. | Mar 2003 | B1 |
| 6533780 | Laird et al. | Mar 2003 | B1 |
| 6536427 | Davies et al. | Mar 2003 | B2 |
| 6544226 | Gaiser et al. | Apr 2003 | B1 |
| 6544262 | Fleischman | Apr 2003 | B2 |
| 6546928 | Ashurst et al. | Apr 2003 | B1 |
| 6546932 | Nahon et al. | Apr 2003 | B1 |
| 6546934 | Ingle et al. | Apr 2003 | B1 |
| 6547776 | Gaiser et al. | Apr 2003 | B1 |
| 6547788 | Maguire et al. | Apr 2003 | B1 |
| 6549808 | Gisel et al. | Apr 2003 | B1 |
| 6551274 | Heiner | Apr 2003 | B2 |
| 6551310 | Ganz et al. | Apr 2003 | B1 |
| 6558333 | Gilboa et al. | May 2003 | B2 |
| 6558378 | Sherman et al. | May 2003 | B2 |
| 6558381 | Ingle et al. | May 2003 | B2 |
| 6562034 | Edwards et al. | May 2003 | B2 |
| 6572612 | Stewart et al. | Jun 2003 | B2 |
| 6575623 | Werneth | Jun 2003 | B2 |
| 6575969 | Rittman, III et al. | Jun 2003 | B1 |
| 6582427 | Goble et al. | Jun 2003 | B1 |
| 6582430 | Hall | Jun 2003 | B2 |
| 6587718 | Talpade | Jul 2003 | B2 |
| 6587719 | Barrett et al. | Jul 2003 | B1 |
| 6587731 | Ingle et al. | Jul 2003 | B1 |
| 6589235 | Wong et al. | Jul 2003 | B2 |
| 6589238 | Edwards et al. | Jul 2003 | B2 |
| 6593130 | Sen et al. | Jul 2003 | B1 |
| 6599311 | Biggs et al. | Jul 2003 | B1 |
| 6601581 | Babaev | Aug 2003 | B1 |
| 6603996 | Beatty et al. | Aug 2003 | B1 |
| 6610054 | Edwards et al. | Aug 2003 | B1 |
| 6610083 | Keller et al. | Aug 2003 | B2 |
| 6610713 | Tracey | Aug 2003 | B2 |
| 6613002 | Clark et al. | Sep 2003 | B1 |
| 6613045 | Laufer et al. | Sep 2003 | B1 |
| 6620159 | Hegde | Sep 2003 | B2 |
| 6620415 | Donovan | Sep 2003 | B2 |
| 6622047 | Barrett et al. | Sep 2003 | B2 |
| 6623742 | Voet | Sep 2003 | B2 |
| 6626855 | Weng et al. | Sep 2003 | B1 |
| 6626903 | McGuckin, Jr. et al. | Sep 2003 | B2 |
| 6629535 | Ingle et al. | Oct 2003 | B2 |
| 6629951 | Laufer et al. | Oct 2003 | B2 |
| 6632440 | Quinn et al. | Oct 2003 | B1 |
| 6633779 | Schuler et al. | Oct 2003 | B1 |
| 6634363 | Danek et al. | Oct 2003 | B1 |
| 6635054 | Fjield et al. | Oct 2003 | B2 |
| 6635056 | Kadhiresan et al. | Oct 2003 | B2 |
| 6638273 | Farley et al. | Oct 2003 | B1 |
| 6640119 | Budd et al. | Oct 2003 | B1 |
| 6640120 | Swanson et al. | Oct 2003 | B1 |
| 6645200 | Koblish et al. | Nov 2003 | B1 |
| 6645496 | Aoki et al. | Nov 2003 | B2 |
| 6647617 | Beatty et al. | Nov 2003 | B1 |
| 6648881 | KenKnight et al. | Nov 2003 | B2 |
| 6649161 | Donovan | Nov 2003 | B1 |
| 6652517 | Hall et al. | Nov 2003 | B1 |
| 6652548 | Evans et al. | Nov 2003 | B2 |
| 6656960 | Puskas | Dec 2003 | B2 |
| 6658279 | Swanson et al. | Dec 2003 | B2 |
| 6663622 | Foley et al. | Dec 2003 | B1 |
| 6666858 | Lafontaine | Dec 2003 | B2 |
| 6669693 | Friedman | Dec 2003 | B2 |
| 6673068 | Berube | Jan 2004 | B1 |
| 6673070 | Edwards et al. | Jan 2004 | B2 |
| 6675047 | Konoplev et al. | Jan 2004 | B1 |
| 6676686 | Naganuma | Jan 2004 | B2 |
| 6681136 | Schuler et al. | Jan 2004 | B2 |
| 6692492 | Simpson et al. | Feb 2004 | B2 |
| 6692494 | Cooper et al. | Feb 2004 | B1 |
| 6699180 | Kobayashi | Mar 2004 | B2 |
| 6699243 | West et al. | Mar 2004 | B2 |
| 6708064 | Rezai | Mar 2004 | B2 |
| 6711436 | Duhaylongsod | Mar 2004 | B1 |
| 6712074 | Edwards et al. | Mar 2004 | B2 |
| 6712812 | Roschak et al. | Mar 2004 | B2 |
| 6712814 | Edwards et al. | Mar 2004 | B2 |
| 6714822 | King et al. | Mar 2004 | B2 |
| 6719685 | Fujikura et al. | Apr 2004 | B2 |
| 6719694 | Weng et al. | Apr 2004 | B2 |
| 6723053 | Ackerman et al. | Apr 2004 | B2 |
| 6723091 | Goble et al. | Apr 2004 | B2 |
| 6728562 | Budd et al. | Apr 2004 | B1 |
| 6735471 | Hill et al. | May 2004 | B2 |
| 6735475 | Whitehurst et al. | May 2004 | B1 |
| 6740321 | Donovan | May 2004 | B1 |
| 6743197 | Edwards | Jun 2004 | B1 |
| 6743413 | Schultz et al. | Jun 2004 | B1 |
| 6749604 | Eggers et al. | Jun 2004 | B1 |
| 6749606 | Keast et al. | Jun 2004 | B2 |
| 6752765 | Strobel et al. | Jun 2004 | B1 |
| 6755026 | Wallach | Jun 2004 | B2 |
| 6755849 | Gowda et al. | Jun 2004 | B1 |
| 6767347 | Sharkey et al. | Jul 2004 | B2 |
| 6767544 | Brooks et al. | Jul 2004 | B2 |
| 6770070 | Balbierz | Aug 2004 | B1 |
| 6772013 | Ingle et al. | Aug 2004 | B1 |
| 6773711 | Voet et al. | Aug 2004 | B2 |
| 6776991 | Naumann | Aug 2004 | B2 |
| 6777423 | Banholzer et al. | Aug 2004 | B2 |
| 6778854 | Puskas | Aug 2004 | B2 |
| 6780183 | Jimenez et al. | Aug 2004 | B2 |
| 6786889 | Musbach et al. | Sep 2004 | B1 |
| 6802843 | Truckai et al. | Oct 2004 | B2 |
| 6805131 | Kordis | Oct 2004 | B2 |
| 6819956 | DiLorenzo | Nov 2004 | B2 |
| 6826420 | Beatty et al. | Nov 2004 | B1 |
| 6826421 | Beatty et al. | Nov 2004 | B1 |
| 6827931 | Donovan | Dec 2004 | B1 |
| 6836688 | Ingle et al. | Dec 2004 | B2 |
| 6837888 | Ciarrocca et al. | Jan 2005 | B2 |
| 6838429 | Paslin | Jan 2005 | B2 |
| 6838434 | Voet | Jan 2005 | B2 |
| 6838471 | Tracey | Jan 2005 | B2 |
| 6840243 | Deem et al. | Jan 2005 | B2 |
| 6841156 | Aoki et al. | Jan 2005 | B2 |
| 6843998 | Steward et al. | Jan 2005 | B1 |
| 6846312 | Edwards et al. | Jan 2005 | B2 |
| 6847849 | Mamo et al. | Jan 2005 | B2 |
| 6849073 | Hoey et al. | Feb 2005 | B2 |
| 6852091 | Edwards et al. | Feb 2005 | B2 |
| 6852110 | Roy et al. | Feb 2005 | B2 |
| 6861058 | Aoki et al. | Mar 2005 | B2 |
| 6866662 | Fuimaono et al. | Mar 2005 | B2 |
| 6871092 | Piccone | Mar 2005 | B2 |
| 6872206 | Edwards et al. | Mar 2005 | B2 |
| 6872397 | Aoki et al. | Mar 2005 | B2 |
| 6878156 | Noda | Apr 2005 | B1 |
| 6881213 | Ryan et al. | Apr 2005 | B2 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6890347 | Machold et al. | May 2005 | B2 |
| 6893436 | Woodard et al. | May 2005 | B2 |
| 6893438 | Hall et al. | May 2005 | B2 |
| 6893439 | Fleischman | May 2005 | B2 |
| 6895267 | Panescu et al. | May 2005 | B2 |
| 6904303 | Phan et al. | Jun 2005 | B2 |
| 6908462 | Joye et al. | Jun 2005 | B2 |
| 6908928 | Banholzer et al. | Jun 2005 | B2 |
| 6913616 | Hamilton et al. | Jul 2005 | B2 |
| 6917834 | Koblish et al. | Jul 2005 | B2 |
| 6934583 | Weinberg et al. | Aug 2005 | B2 |
| 6937896 | Kroll | Aug 2005 | B1 |
| 6937903 | Schuler et al. | Aug 2005 | B2 |
| 6939309 | Beatty et al. | Sep 2005 | B1 |
| 6939345 | KenKnight et al. | Sep 2005 | B2 |
| 6939346 | Kannenberg et al. | Sep 2005 | B2 |
| 6947785 | Beatty et al. | Sep 2005 | B1 |
| 6954977 | Maguire et al. | Oct 2005 | B2 |
| 6957106 | Schuler et al. | Oct 2005 | B2 |
| 6961622 | Gilbert | Nov 2005 | B2 |
| 6970742 | Mann et al. | Nov 2005 | B2 |
| RE38912 | Walz et al. | Dec 2005 | E |
| 6971395 | Edwards et al. | Dec 2005 | B2 |
| 6974224 | Thomas-Benedict | Dec 2005 | B2 |
| 6974456 | Edwards et al. | Dec 2005 | B2 |
| 6974578 | Aoki et al. | Dec 2005 | B1 |
| 6978168 | Beatty et al. | Dec 2005 | B2 |
| 6978174 | Gelfand et al. | Dec 2005 | B2 |
| 6990370 | Beatty et al. | Jan 2006 | B1 |
| 6994706 | Chornenky et al. | Feb 2006 | B2 |
| 6997189 | Biggs et al. | Feb 2006 | B2 |
| 7004942 | Laird et al. | Feb 2006 | B2 |
| 7022088 | Keast et al. | Apr 2006 | B2 |
| 7022105 | Edwards | Apr 2006 | B1 |
| 7027869 | Danek et al. | Apr 2006 | B2 |
| 7043307 | Zelickson et al. | May 2006 | B1 |
| 7070800 | Bechtold-Peters et al. | Jul 2006 | B2 |
| 7072720 | Puskas | Jul 2006 | B2 |
| 7083614 | Fjield et al. | Aug 2006 | B2 |
| 7101368 | Lafontaine | Sep 2006 | B2 |
| 7101387 | Garabedian et al. | Sep 2006 | B2 |
| 7104987 | Biggs et al. | Sep 2006 | B2 |
| 7104990 | Jenkins et al. | Sep 2006 | B2 |
| 7112198 | Satake | Sep 2006 | B2 |
| 7118568 | Hassett et al. | Oct 2006 | B2 |
| 7122031 | Edwards et al. | Oct 2006 | B2 |
| 7122033 | Wood | Oct 2006 | B2 |
| 7125407 | Edwards et al. | Oct 2006 | B2 |
| 7131445 | Amoah | Nov 2006 | B2 |
| 7142910 | Puskas | Nov 2006 | B2 |
| 7150745 | Stern et al. | Dec 2006 | B2 |
| 7162303 | Levin et al. | Jan 2007 | B2 |
| 7165551 | Edwards et al. | Jan 2007 | B2 |
| 7167757 | Ingle et al. | Jan 2007 | B2 |
| 7175644 | Cooper et al. | Feb 2007 | B2 |
| 7179257 | West et al. | Feb 2007 | B2 |
| 7186251 | Malecki et al. | Mar 2007 | B2 |
| 7187964 | Khoury | Mar 2007 | B2 |
| 7187973 | Hauck | Mar 2007 | B2 |
| 7189208 | Beatty et al. | Mar 2007 | B1 |
| 7198635 | Danek et al. | Apr 2007 | B2 |
| 7200445 | Dalbec et al. | Apr 2007 | B1 |
| 7229469 | Witzel et al. | Jun 2007 | B1 |
| 7238357 | Barron | Jul 2007 | B2 |
| 7241295 | Maguire | Jul 2007 | B2 |
| 7255693 | Johnston et al. | Aug 2007 | B1 |
| RE39820 | Banholzer et al. | Sep 2007 | E |
| 7264002 | Danek et al. | Sep 2007 | B2 |
| 7266414 | Cornelius et al. | Sep 2007 | B2 |
| 7273055 | Danek et al. | Sep 2007 | B2 |
| 7289843 | Beatty et al. | Oct 2007 | B2 |
| 7291146 | Steinke et al. | Nov 2007 | B2 |
| 7292890 | Whitehurst et al. | Nov 2007 | B2 |
| 7309707 | Bender et al. | Dec 2007 | B2 |
| 7310552 | Puskas | Dec 2007 | B2 |
| RE40045 | Palmer | Feb 2008 | E |
| 7326207 | Edwards | Feb 2008 | B2 |
| 7344535 | Stern et al. | Mar 2008 | B2 |
| 7371231 | Rioux et al. | May 2008 | B2 |
| 7393330 | Keast et al. | Jul 2008 | B2 |
| 7393350 | Maurice | Jul 2008 | B2 |
| 7394976 | Entenman et al. | Jul 2008 | B2 |
| 7402172 | Chin et al. | Jul 2008 | B2 |
| 7422563 | Roschak et al. | Sep 2008 | B2 |
| 7422584 | Loomas et al. | Sep 2008 | B2 |
| 7425212 | Danek et al. | Sep 2008 | B1 |
| 7430449 | Aldrich et al. | Sep 2008 | B2 |
| 7462162 | Phan et al. | Dec 2008 | B2 |
| 7462179 | Edwards et al. | Dec 2008 | B2 |
| 7473273 | Campbell | Jan 2009 | B2 |
| 7477945 | Rezai et al. | Jan 2009 | B2 |
| 7483755 | Ingle et al. | Jan 2009 | B2 |
| 7493160 | Weber et al. | Feb 2009 | B2 |
| 7494661 | Sanders | Feb 2009 | B2 |
| 7507234 | Utley et al. | Mar 2009 | B2 |
| 7507238 | Edwards et al. | Mar 2009 | B2 |
| 7517320 | Wibowo et al. | Apr 2009 | B2 |
| 7530979 | Ganz et al. | May 2009 | B2 |
| 7532938 | Machado et al. | May 2009 | B2 |
| 7542802 | Danek et al. | Jun 2009 | B2 |
| 7553307 | Bleich et al. | Jun 2009 | B2 |
| 7556624 | Laufer et al. | Jul 2009 | B2 |
| 7559890 | Wallace et al. | Jul 2009 | B2 |
| 7572245 | Herweck et al. | Aug 2009 | B2 |
| 7585296 | Edwards et al. | Sep 2009 | B2 |
| 7588549 | Eccleston | Sep 2009 | B2 |
| 7594925 | Danek et al. | Sep 2009 | B2 |
| 7608275 | Deem et al. | Oct 2009 | B2 |
| 7613515 | Knudson et al. | Nov 2009 | B2 |
| 7617005 | Demarais et al. | Nov 2009 | B2 |
| 7620451 | Demarais et al. | Nov 2009 | B2 |
| 7628789 | Soltesz et al. | Dec 2009 | B2 |
| 7632268 | Edwards et al. | Dec 2009 | B2 |
| 7641632 | Noda et al. | Jan 2010 | B2 |
| 7641633 | Laufer et al. | Jan 2010 | B2 |
| 7648500 | Edwards et al. | Jan 2010 | B2 |
| 7653438 | Deem et al. | Jan 2010 | B2 |
| 7684865 | Aldrich et al. | Mar 2010 | B2 |
| 7689290 | Ingle et al. | Mar 2010 | B2 |
| 7691079 | Gobel | Apr 2010 | B2 |
| RE41334 | Beatty et al. | May 2010 | E |
| 7708712 | Phan et al. | May 2010 | B2 |
| 7708768 | Danek et al. | May 2010 | B2 |
| 7711430 | Errico et al. | May 2010 | B2 |
| 7717948 | Demarais et al. | May 2010 | B2 |
| 7722538 | Khoury | May 2010 | B2 |
| 7725188 | Errico et al. | May 2010 | B2 |
| 7734355 | Cohen et al. | Jun 2010 | B2 |
| 7734535 | Burns | Jun 2010 | B1 |
| 7740017 | Danek et al. | Jun 2010 | B2 |
| 7740631 | Bleich et al. | Jun 2010 | B2 |
| 7742795 | Stone et al. | Jun 2010 | B2 |
| 7747324 | Errico et al. | Jun 2010 | B2 |
| 7756583 | Demarais et al. | Jul 2010 | B2 |
| 7765010 | Chornenky et al. | Jul 2010 | B2 |
| 7770584 | Danek et al. | Aug 2010 | B2 |
| 7783358 | Aldrich et al. | Aug 2010 | B2 |
| 7815590 | Cooper | Oct 2010 | B2 |
| 7826881 | Beatty et al. | Nov 2010 | B1 |
| 7831288 | Beatty et al. | Nov 2010 | B1 |
| 7837676 | Sinelnikov et al. | Nov 2010 | B2 |
| 7837679 | Biggs et al. | Nov 2010 | B2 |
| 7841986 | He et al. | Nov 2010 | B2 |
| 7844338 | Knudson et al. | Nov 2010 | B2 |
| 7853331 | Kaplan et al. | Dec 2010 | B2 |
| 7854734 | Biggs et al. | Dec 2010 | B2 |
| 7854740 | Carney | Dec 2010 | B2 |
| 7869879 | Errico et al. | Jan 2011 | B2 |
| 7869880 | Errico et al. | Jan 2011 | B2 |
| 7873417 | Demarais et al. | Jan 2011 | B2 |
| 7877146 | Rezai et al. | Jan 2011 | B2 |
| 7904159 | Errico et al. | Mar 2011 | B2 |
| 7906124 | Laufer et al. | Mar 2011 | B2 |
| 7914448 | Bob et al. | Mar 2011 | B2 |
| 7921855 | Danek et al. | Apr 2011 | B2 |
| 7930012 | Beatty et al. | Apr 2011 | B2 |
| 7931647 | Wizeman et al. | Apr 2011 | B2 |
| 7937143 | Demarais et al. | May 2011 | B2 |
| 7938123 | Danek et al. | May 2011 | B2 |
| 7949407 | Kaplan et al. | May 2011 | B2 |
| 7967782 | Laufer et al. | Jun 2011 | B2 |
| 7985187 | Wibowo et al. | Jul 2011 | B2 |
| 7992572 | Danek et al. | Aug 2011 | B2 |
| 7993336 | Jackson et al. | Aug 2011 | B2 |
| 8002740 | Willink et al. | Aug 2011 | B2 |
| 8007495 | McDaniel et al. | Aug 2011 | B2 |
| 8010197 | Errico et al. | Aug 2011 | B2 |
| 8012149 | Jackson et al. | Sep 2011 | B2 |
| 8041428 | Errico et al. | Oct 2011 | B2 |
| 8046085 | Knudson et al. | Oct 2011 | B2 |
| 8052668 | Sih | Nov 2011 | B2 |
| 8088127 | Mayse et al. | Jan 2012 | B2 |
| 8099167 | Errico et al. | Jan 2012 | B1 |
| 8105817 | Deem et al. | Jan 2012 | B2 |
| 8128595 | Walker et al. | Mar 2012 | B2 |
| 8128617 | Bencini et al. | Mar 2012 | B2 |
| 8131371 | Demarals et al. | Mar 2012 | B2 |
| 8133497 | Deem et al. | Mar 2012 | B2 |
| 8152803 | Edwards et al. | Apr 2012 | B2 |
| 8172827 | Deem et al. | May 2012 | B2 |
| 8204598 | Errico et al. | Jun 2012 | B2 |
| 8208998 | Beatty et al. | Jun 2012 | B2 |
| 8209034 | Simon et al. | Jun 2012 | B2 |
| 8216216 | Warnking et al. | Jul 2012 | B2 |
| 8226638 | Mayse et al. | Jul 2012 | B2 |
| 8229564 | Rezai | Jul 2012 | B2 |
| 8231621 | Hutchins et al. | Jul 2012 | B2 |
| 8233988 | Errico et al. | Jul 2012 | B2 |
| 8251992 | Utley et al. | Aug 2012 | B2 |
| 8267094 | Danek et al. | Sep 2012 | B2 |
| 8295902 | Salahieh et al. | Oct 2012 | B2 |
| 8303581 | Arts et al. | Nov 2012 | B2 |
| 8313484 | Edwards et al. | Nov 2012 | B2 |
| 8328798 | Witzel et al. | Dec 2012 | B2 |
| 8338164 | Deem et al. | Dec 2012 | B2 |
| 8347891 | Demarais et al. | Jan 2013 | B2 |
| 8357118 | Orr | Jan 2013 | B2 |
| 8364237 | Stone et al. | Jan 2013 | B2 |
| 8371303 | Schaner et al. | Feb 2013 | B2 |
| 8377055 | Jackson et al. | Feb 2013 | B2 |
| 8483831 | Hlavka et al. | Jul 2013 | B1 |
| 8489192 | Hlavka et al. | Jul 2013 | B1 |
| 8731672 | Hlavka et al. | May 2014 | B2 |
| 8740895 | Mayse et al. | Jun 2014 | B2 |
| 8777943 | Mayse et al. | Jul 2014 | B2 |
| 8808280 | Mayse et al. | Aug 2014 | B2 |
| 8821489 | Mayse et al. | Sep 2014 | B2 |
| 8911439 | Mayse et al. | Dec 2014 | B2 |
| 20010020151 | Reed et al. | Sep 2001 | A1 |
| 20010044596 | Jaafar | Nov 2001 | A1 |
| 20020002387 | Naganuma | Jan 2002 | A1 |
| 20020010495 | Freed et al. | Jan 2002 | A1 |
| 20020013581 | Edwards et al. | Jan 2002 | A1 |
| 20020016344 | Tracey | Feb 2002 | A1 |
| 20020042564 | Cooper et al. | Apr 2002 | A1 |
| 20020042565 | Cooper et al. | Apr 2002 | A1 |
| 20020049370 | Laufer et al. | Apr 2002 | A1 |
| 20020072738 | Edwards et al. | Jun 2002 | A1 |
| 20020082197 | Aoki et al. | Jun 2002 | A1 |
| 20020087153 | Roschak et al. | Jul 2002 | A1 |
| 20020087208 | Koblish | Jul 2002 | A1 |
| 20020091379 | Danek et al. | Jul 2002 | A1 |
| 20020107512 | Edwards | Aug 2002 | A1 |
| 20020107515 | Edwards et al. | Aug 2002 | A1 |
| 20020111386 | Sekins et al. | Aug 2002 | A1 |
| 20020111619 | Keast et al. | Aug 2002 | A1 |
| 20020111620 | Cooper et al. | Aug 2002 | A1 |
| 20020115991 | Edwards | Aug 2002 | A1 |
| 20020116030 | Rezai | Aug 2002 | A1 |
| 20020143302 | Hinchliffe et al. | Oct 2002 | A1 |
| 20020143326 | Foley et al. | Oct 2002 | A1 |
| 20020143373 | Courtnage et al. | Oct 2002 | A1 |
| 20020151888 | Edwards et al. | Oct 2002 | A1 |
| 20020183682 | Darvish et al. | Dec 2002 | A1 |
| 20020198512 | Seward | Dec 2002 | A1 |
| 20020198570 | Puskas | Dec 2002 | A1 |
| 20020198574 | Gumpert | Dec 2002 | A1 |
| 20030018344 | Kaji et al. | Jan 2003 | A1 |
| 20030023287 | Edwards | Jan 2003 | A1 |
| 20030027752 | Steward et al. | Feb 2003 | A1 |
| 20030050591 | McHale | Mar 2003 | A1 |
| 20030050631 | Mody et al. | Mar 2003 | A1 |
| 20030065371 | Satake | Apr 2003 | A1 |
| 20030069570 | Witzel et al. | Apr 2003 | A1 |
| 20030070676 | Cooper et al. | Apr 2003 | A1 |
| 20030074039 | Puskas | Apr 2003 | A1 |
| 20030093069 | Panescu et al. | May 2003 | A1 |
| 20030093128 | Freed et al. | May 2003 | A1 |
| 20030125786 | Gliner et al. | Jul 2003 | A1 |
| 20030130657 | Tom et al. | Jul 2003 | A1 |
| 20030144572 | Oschman et al. | Jul 2003 | A1 |
| 20030153905 | Edwards et al. | Aug 2003 | A1 |
| 20030159700 | Laufer et al. | Aug 2003 | A1 |
| 20030181949 | Whale | Sep 2003 | A1 |
| 20030187430 | Vorisek | Oct 2003 | A1 |
| 20030195593 | Ingle et al. | Oct 2003 | A1 |
| 20030195604 | Ingle et al. | Oct 2003 | A1 |
| 20030202990 | Donovan et al. | Oct 2003 | A1 |
| 20030208103 | Sonnenschein et al. | Nov 2003 | A1 |
| 20030211121 | Donovan | Nov 2003 | A1 |
| 20030216791 | Schuler et al. | Nov 2003 | A1 |
| 20030216792 | Levin et al. | Nov 2003 | A1 |
| 20030216891 | Wegener | Nov 2003 | A1 |
| 20030225443 | Kiran et al. | Dec 2003 | A1 |
| 20030233099 | Danaek et al. | Dec 2003 | A1 |
| 20030236455 | Swanson et al. | Dec 2003 | A1 |
| 20040006268 | Gilboa et al. | Jan 2004 | A1 |
| 20040009180 | Donovan | Jan 2004 | A1 |
| 20040010289 | Biggs et al. | Jan 2004 | A1 |
| 20040010290 | Schroeppel et al. | Jan 2004 | A1 |
| 20040028676 | Klein et al. | Feb 2004 | A1 |
| 20040029849 | Schatzberg et al. | Feb 2004 | A1 |
| 20040030368 | Kemeny et al. | Feb 2004 | A1 |
| 20040031494 | Danek et al. | Feb 2004 | A1 |
| 20040044390 | Szeles | Mar 2004 | A1 |
| 20040059383 | Puskas | Mar 2004 | A1 |
| 20040073201 | Cooper et al. | Apr 2004 | A1 |
| 20040073206 | Foley et al. | Apr 2004 | A1 |
| 20040073278 | Pachys | Apr 2004 | A1 |
| 20040086531 | Barron | May 2004 | A1 |
| 20040087936 | Stern et al. | May 2004 | A1 |
| 20040088030 | Jung, Jr. | May 2004 | A1 |
| 20040088036 | Gilbert | May 2004 | A1 |
| 20040091880 | Wiebusch et al. | May 2004 | A1 |
| 20040106954 | Whitehurst et al. | Jun 2004 | A1 |
| 20040116981 | Mazar | Jun 2004 | A1 |
| 20040122488 | Mazar et al. | Jun 2004 | A1 |
| 20040122489 | Mazar et al. | Jun 2004 | A1 |
| 20040127942 | Yomtov et al. | Jul 2004 | A1 |
| 20040127958 | Mazar et al. | Jul 2004 | A1 |
| 20040142005 | Brooks et al. | Jul 2004 | A1 |
| 20040147921 | Edwards et al. | Jul 2004 | A1 |
| 20040147969 | Mann et al. | Jul 2004 | A1 |
| 20040147988 | Stephens | Jul 2004 | A1 |
| 20040151741 | Borodic | Aug 2004 | A1 |
| 20040153056 | Muller et al. | Aug 2004 | A1 |
| 20040158237 | Abboud et al. | Aug 2004 | A1 |
| 20040162584 | Hill et al. | Aug 2004 | A1 |
| 20040162597 | Hamilton et al. | Aug 2004 | A1 |
| 20040167509 | Taimisto | Aug 2004 | A1 |
| 20040167580 | Mann et al. | Aug 2004 | A1 |
| 20040172075 | Shafer et al. | Sep 2004 | A1 |
| 20040172080 | Stadler et al. | Sep 2004 | A1 |
| 20040172084 | Knudson et al. | Sep 2004 | A1 |
| 20040175399 | Schiffman | Sep 2004 | A1 |
| 20040176803 | Whelan et al. | Sep 2004 | A1 |
| 20040176805 | Whelan et al. | Sep 2004 | A1 |
| 20040182399 | Danek et al. | Sep 2004 | A1 |
| 20040186435 | Seward | Sep 2004 | A1 |
| 20040204747 | Kemeny et al. | Oct 2004 | A1 |
| 20040213813 | Ackerman | Oct 2004 | A1 |
| 20040213814 | Ackerman | Oct 2004 | A1 |
| 20040215235 | Jackson et al. | Oct 2004 | A1 |
| 20040215289 | Fukui | Oct 2004 | A1 |
| 20040215296 | Ganz et al. | Oct 2004 | A1 |
| 20040220556 | Cooper et al. | Nov 2004 | A1 |
| 20040220621 | Zhou et al. | Nov 2004 | A1 |
| 20040226556 | Deem et al. | Nov 2004 | A1 |
| 20040230251 | Schuler et al. | Nov 2004 | A1 |
| 20040230252 | Kullok et al. | Nov 2004 | A1 |
| 20040243118 | Ayers et al. | Dec 2004 | A1 |
| 20040243182 | Cohen et al. | Dec 2004 | A1 |
| 20040248188 | Sanders | Dec 2004 | A1 |
| 20040249401 | Rabiner et al. | Dec 2004 | A1 |
| 20040249416 | Yun et al. | Dec 2004 | A1 |
| 20040253274 | Voet | Dec 2004 | A1 |
| 20050004609 | Stahmann et al. | Jan 2005 | A1 |
| 20050004631 | Benedict | Jan 2005 | A1 |
| 20050010263 | Schauerte | Jan 2005 | A1 |
| 20050010270 | Laufer | Jan 2005 | A1 |
| 20050015117 | Gerber | Jan 2005 | A1 |
| 20050019346 | Boulis | Jan 2005 | A1 |
| 20050021092 | Yun et al. | Jan 2005 | A1 |
| 20050049615 | Cooper et al. | Mar 2005 | A1 |
| 20050056292 | Cooper | Mar 2005 | A1 |
| 20050059153 | George et al. | Mar 2005 | A1 |
| 20050060041 | Phan et al. | Mar 2005 | A1 |
| 20050060042 | Phan et al. | Mar 2005 | A1 |
| 20050060044 | Roschak et al. | Mar 2005 | A1 |
| 20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
| 20050065562 | Rezai | Mar 2005 | A1 |
| 20050065567 | Lee et al. | Mar 2005 | A1 |
| 20050065573 | Rezai | Mar 2005 | A1 |
| 20050065574 | Rezai | Mar 2005 | A1 |
| 20050065575 | Dobak | Mar 2005 | A1 |
| 20050065584 | Schiff et al. | Mar 2005 | A1 |
| 20050074461 | Donovan | Apr 2005 | A1 |
| 20050076909 | Stahmann et al. | Apr 2005 | A1 |
| 20050080461 | Stahmann et al. | Apr 2005 | A1 |
| 20050085801 | Cooper et al. | Apr 2005 | A1 |
| 20050090722 | Perez | Apr 2005 | A1 |
| 20050096529 | Cooper et al. | May 2005 | A1 |
| 20050096644 | Hall et al. | May 2005 | A1 |
| 20050107783 | Tom et al. | May 2005 | A1 |
| 20050107829 | Edwards et al. | May 2005 | A1 |
| 20050107853 | Krespi et al. | May 2005 | A1 |
| 20050125044 | Tracey | Jun 2005 | A1 |
| 20050137518 | Biggs et al. | Jun 2005 | A1 |
| 20050137611 | Escudero et al. | Jun 2005 | A1 |
| 20050137715 | Phan et al. | Jun 2005 | A1 |
| 20050143788 | Yun et al. | Jun 2005 | A1 |
| 20050149146 | Boveja et al. | Jul 2005 | A1 |
| 20050152924 | Voet | Jul 2005 | A1 |
| 20050153885 | Yun et al. | Jul 2005 | A1 |
| 20050159736 | Danek et al. | Jul 2005 | A9 |
| 20050165456 | Mann et al. | Jul 2005 | A1 |
| 20050171396 | Pankratov et al. | Aug 2005 | A1 |
| 20050177144 | Phan et al. | Aug 2005 | A1 |
| 20050177192 | Rezai et al. | Aug 2005 | A1 |
| 20050182288 | Zabara | Aug 2005 | A1 |
| 20050182393 | Abboud et al. | Aug 2005 | A1 |
| 20050183732 | Edwards | Aug 2005 | A1 |
| 20050187579 | Danek et al. | Aug 2005 | A1 |
| 20050193279 | Daners | Sep 2005 | A1 |
| 20050203503 | Edwards et al. | Sep 2005 | A1 |
| 20050222628 | Krakousky | Oct 2005 | A1 |
| 20050222635 | Krakousky | Oct 2005 | A1 |
| 20050222651 | Jung, Jr. | Oct 2005 | A1 |
| 20050228054 | Tatton | Oct 2005 | A1 |
| 20050228459 | Levin et al. | Oct 2005 | A1 |
| 20050228460 | Levin et al. | Oct 2005 | A1 |
| 20050234523 | Levin et al. | Oct 2005 | A1 |
| 20050238693 | Whyte | Oct 2005 | A1 |
| 20050240176 | Oral et al. | Oct 2005 | A1 |
| 20050240241 | Yun et al. | Oct 2005 | A1 |
| 20050245926 | Edwards et al. | Nov 2005 | A1 |
| 20050245992 | Persen et al. | Nov 2005 | A1 |
| 20050251128 | Amoah | Nov 2005 | A1 |
| 20050251213 | Freeman | Nov 2005 | A1 |
| 20050255317 | Bavaro et al. | Nov 2005 | A1 |
| 20050256028 | Yun et al. | Nov 2005 | A1 |
| 20050261747 | Schuler et al. | Nov 2005 | A1 |
| 20050267536 | Freeman et al. | Dec 2005 | A1 |
| 20050277993 | Mower | Dec 2005 | A1 |
| 20050283197 | Daum et al. | Dec 2005 | A1 |
| 20060009758 | Edwards et al. | Jan 2006 | A1 |
| 20060015151 | Aldrich | Jan 2006 | A1 |
| 20060058692 | Beatty et al. | Mar 2006 | A1 |
| 20060058693 | Beatty et al. | Mar 2006 | A1 |
| 20060058780 | Edwards et al. | Mar 2006 | A1 |
| 20060062808 | Laufer et al. | Mar 2006 | A1 |
| 20060079887 | Buysse et al. | Apr 2006 | A1 |
| 20060084884 | Beatty et al. | Apr 2006 | A1 |
| 20060084966 | Maguire et al. | Apr 2006 | A1 |
| 20060084970 | Beatty et al. | Apr 2006 | A1 |
| 20060084971 | Beatty et al. | Apr 2006 | A1 |
| 20060084972 | Beatty et al. | Apr 2006 | A1 |
| 20060089637 | Werneth et al. | Apr 2006 | A1 |
| 20060095032 | Jackson et al. | May 2006 | A1 |
| 20060100666 | Wilkinson et al. | May 2006 | A1 |
| 20060106361 | Muni et al. | May 2006 | A1 |
| 20060111755 | Stone et al. | May 2006 | A1 |
| 20060116749 | Willink et al. | Jun 2006 | A1 |
| 20060135953 | Kania et al. | Jun 2006 | A1 |
| 20060135984 | Kramer et al. | Jun 2006 | A1 |
| 20060135998 | Libbus et al. | Jun 2006 | A1 |
| 20060137698 | Danek et al. | Jun 2006 | A1 |
| 20060142801 | Demarais et al. | Jun 2006 | A1 |
| 20060167498 | DiLorenzo | Jul 2006 | A1 |
| 20060178703 | Huston et al. | Aug 2006 | A1 |
| 20060206150 | Demarais et al. | Sep 2006 | A1 |
| 20060212076 | Demarais et al. | Sep 2006 | A1 |
| 20060212078 | Demarais et al. | Sep 2006 | A1 |
| 20060222667 | Deem et al. | Oct 2006 | A1 |
| 20060225742 | Deem et al. | Oct 2006 | A1 |
| 20060235474 | Demarais | Oct 2006 | A1 |
| 20060241523 | Sinelnikov et al. | Oct 2006 | A1 |
| 20060247617 | Danek et al. | Nov 2006 | A1 |
| 20060247618 | Kaplan et al. | Nov 2006 | A1 |
| 20060247619 | Kaplan et al. | Nov 2006 | A1 |
| 20060247683 | Danek et al. | Nov 2006 | A1 |
| 20060247726 | Biggs et al. | Nov 2006 | A1 |
| 20060247727 | Biggs et al. | Nov 2006 | A1 |
| 20060247746 | Danek et al. | Nov 2006 | A1 |
| 20060254600 | Danek et al. | Nov 2006 | A1 |
| 20060259028 | Utley et al. | Nov 2006 | A1 |
| 20060259029 | Utley et al. | Nov 2006 | A1 |
| 20060259030 | Utley et al. | Nov 2006 | A1 |
| 20060265014 | Demarais et al. | Nov 2006 | A1 |
| 20060265015 | Demarais et al. | Nov 2006 | A1 |
| 20060271111 | Demarais et al. | Nov 2006 | A1 |
| 20060276807 | Keast et al. | Dec 2006 | A1 |
| 20060276852 | Demarais et al. | Dec 2006 | A1 |
| 20060278243 | Danek et al. | Dec 2006 | A1 |
| 20060278244 | Danek et al. | Dec 2006 | A1 |
| 20060280772 | Roschak et al. | Dec 2006 | A1 |
| 20060280773 | Roschak et al. | Dec 2006 | A1 |
| 20060282071 | Utley et al. | Dec 2006 | A1 |
| 20060287679 | Stone | Dec 2006 | A1 |
| 20070021803 | Deem et al. | Jan 2007 | A1 |
| 20070025919 | Deem et al. | Feb 2007 | A1 |
| 20070027496 | Parnis et al. | Feb 2007 | A1 |
| 20070032788 | Edwards et al. | Feb 2007 | A1 |
| 20070043342 | Kleinberger | Feb 2007 | A1 |
| 20070055328 | Mayse et al. | Mar 2007 | A1 |
| 20070060954 | Cameron et al. | Mar 2007 | A1 |
| 20070060990 | Satake | Mar 2007 | A1 |
| 20070062545 | Danek et al. | Mar 2007 | A1 |
| 20070066957 | Demarais et al. | Mar 2007 | A1 |
| 20070074719 | Danek et al. | Apr 2007 | A1 |
| 20070083194 | Kunis et al. | Apr 2007 | A1 |
| 20070083197 | Danek et al. | Apr 2007 | A1 |
| 20070083239 | Demarais et al. | Apr 2007 | A1 |
| 20070093802 | Danek et al. | Apr 2007 | A1 |
| 20070093809 | Edwards et al. | Apr 2007 | A1 |
| 20070100390 | Danaek et al. | May 2007 | A1 |
| 20070102011 | Danek et al. | May 2007 | A1 |
| 20070106292 | Kaplan et al. | May 2007 | A1 |
| 20070106296 | Laufer et al. | May 2007 | A1 |
| 20070106337 | Errico et al. | May 2007 | A1 |
| 20070106338 | Errico | May 2007 | A1 |
| 20070106339 | Errico et al. | May 2007 | A1 |
| 20070106348 | Laufer | May 2007 | A1 |
| 20070112349 | Danek et al. | May 2007 | A1 |
| 20070118184 | Danek et al. | May 2007 | A1 |
| 20070118190 | Danek et al. | May 2007 | A1 |
| 20070123922 | Cooper et al. | May 2007 | A1 |
| 20070123958 | Laufer | May 2007 | A1 |
| 20070123961 | Danek et al. | May 2007 | A1 |
| 20070129720 | Demarais et al. | Jun 2007 | A1 |
| 20070129760 | Demarais et al. | Jun 2007 | A1 |
| 20070129761 | Demarais et al. | Jun 2007 | A1 |
| 20070135875 | Demarais et al. | Jun 2007 | A1 |
| 20070173899 | Levin et al. | Jul 2007 | A1 |
| 20070191902 | Errico et al. | Aug 2007 | A1 |
| 20070197896 | Moll et al. | Aug 2007 | A1 |
| 20070203549 | Demarais et al. | Aug 2007 | A1 |
| 20070225768 | Dobak | Sep 2007 | A1 |
| 20070232896 | Gilboa et al. | Oct 2007 | A1 |
| 20070239256 | Weber et al. | Oct 2007 | A1 |
| 20070244479 | Beatty et al. | Oct 2007 | A1 |
| 20070250050 | Lafontaine | Oct 2007 | A1 |
| 20070255270 | Carney | Nov 2007 | A1 |
| 20070255304 | Roschak et al. | Nov 2007 | A1 |
| 20070265639 | Danek et al. | Nov 2007 | A1 |
| 20070265687 | Deem et al. | Nov 2007 | A1 |
| 20070267011 | Deem et al. | Nov 2007 | A1 |
| 20080004596 | Yun et al. | Jan 2008 | A1 |
| 20080021274 | Bayer et al. | Jan 2008 | A1 |
| 20080021369 | Deem et al. | Jan 2008 | A1 |
| 20080051839 | Libbus et al. | Feb 2008 | A1 |
| 20080086107 | Roschak | Apr 2008 | A1 |
| 20080097422 | Edwards et al. | Apr 2008 | A1 |
| 20080097424 | Wizeman | Apr 2008 | A1 |
| 20080125772 | Stone et al. | May 2008 | A1 |
| 20080147137 | Cohen et al. | Jun 2008 | A1 |
| 20080154258 | Chang et al. | Jun 2008 | A1 |
| 20080161801 | Steinke et al. | Jul 2008 | A1 |
| 20080183248 | Rezai et al. | Jul 2008 | A1 |
| 20080188912 | Stone et al. | Aug 2008 | A1 |
| 20080188913 | Stone et al. | Aug 2008 | A1 |
| 20080194956 | Aldrich et al. | Aug 2008 | A1 |
| 20080208305 | Rezai et al. | Aug 2008 | A1 |
| 20080213331 | Gelfand et al. | Sep 2008 | A1 |
| 20080234564 | Beatty et al. | Sep 2008 | A1 |
| 20080243112 | De Neve | Oct 2008 | A1 |
| 20080255449 | Warnking et al. | Oct 2008 | A1 |
| 20080255642 | Zarins et al. | Oct 2008 | A1 |
| 20080262489 | Steinke | Oct 2008 | A1 |
| 20080275445 | Kelly et al. | Nov 2008 | A1 |
| 20080302359 | Loomas et al. | Dec 2008 | A1 |
| 20080306570 | Rezai et al. | Dec 2008 | A1 |
| 20080312543 | Laufer et al. | Dec 2008 | A1 |
| 20080312725 | Penner | Dec 2008 | A1 |
| 20080319350 | Wallace et al. | Dec 2008 | A1 |
| 20090018473 | Aldrich et al. | Jan 2009 | A1 |
| 20090018538 | Webster et al. | Jan 2009 | A1 |
| 20090030477 | Jarrard | Jan 2009 | A1 |
| 20090036948 | Levin et al. | Feb 2009 | A1 |
| 20090043301 | Jarrard | Feb 2009 | A1 |
| 20090043302 | Ford et al. | Feb 2009 | A1 |
| 20090048593 | Ganz et al. | Feb 2009 | A1 |
| 20090060953 | Sandars | Mar 2009 | A1 |
| 20090062873 | Wu et al. | Mar 2009 | A1 |
| 20090069797 | Danek et al. | Mar 2009 | A1 |
| 20090076409 | Wu et al. | Mar 2009 | A1 |
| 20090076491 | Roschak et al. | Mar 2009 | A1 |
| 20090112203 | Danek et al. | Apr 2009 | A1 |
| 20090124883 | Wibowo et al. | May 2009 | A1 |
| 20090131765 | Roschak et al. | May 2009 | A1 |
| 20090131928 | Edwards et al. | May 2009 | A1 |
| 20090131930 | Gelbart et al. | May 2009 | A1 |
| 20090143678 | Keast et al. | Jun 2009 | A1 |
| 20090143705 | Danek et al. | Jun 2009 | A1 |
| 20090143776 | Danek et al. | Jun 2009 | A1 |
| 20090143831 | Huston et al. | Jun 2009 | A1 |
| 20090155336 | Rezai | Jun 2009 | A1 |
| 20090177192 | Rioux et al. | Jul 2009 | A1 |
| 20090192505 | Askew et al. | Jul 2009 | A1 |
| 20090192508 | Laufer et al. | Jul 2009 | A1 |
| 20090204005 | Keast et al. | Aug 2009 | A1 |
| 20090204119 | Bleich et al. | Aug 2009 | A1 |
| 20090227885 | Lowery et al. | Sep 2009 | A1 |
| 20090227980 | Kangas et al. | Sep 2009 | A1 |
| 20090232850 | Manack et al. | Sep 2009 | A1 |
| 20090248011 | Hlavka et al. | Oct 2009 | A1 |
| 20090254079 | Edwards et al. | Oct 2009 | A1 |
| 20090254142 | Edwards et al. | Oct 2009 | A1 |
| 20090259274 | Simon et al. | Oct 2009 | A1 |
| 20090275840 | Roschak et al. | Nov 2009 | A1 |
| 20090275878 | Cambier et al. | Nov 2009 | A1 |
| 20090281593 | Errico et al. | Nov 2009 | A9 |
| 20090287087 | Gwerder et al. | Nov 2009 | A1 |
| 20090306644 | Mayse et al. | Dec 2009 | A1 |
| 20090318904 | Cooper et al. | Dec 2009 | A9 |
| 20090319002 | Simon | Dec 2009 | A1 |
| 20100003282 | Deem et al. | Jan 2010 | A1 |
| 20100004648 | Edwards et al. | Jan 2010 | A1 |
| 20100010564 | Simon | Jan 2010 | A1 |
| 20100016709 | Gilboa et al. | Jan 2010 | A1 |
| 20100042089 | Soltesz et al. | Feb 2010 | A1 |
| 20100049031 | Fruland et al. | Feb 2010 | A1 |
| 20100049186 | Ingle et al. | Feb 2010 | A1 |
| 20100049188 | Nelson et al. | Feb 2010 | A1 |
| 20100057178 | Simon | Mar 2010 | A1 |
| 20100063495 | Edwards et al. | Mar 2010 | A1 |
| 20100070004 | Hlavka et al. | Mar 2010 | A1 |
| 20100076518 | Hlavka et al. | Mar 2010 | A1 |
| 20100087783 | Weber et al. | Apr 2010 | A1 |
| 20100087809 | Edwards et al. | Apr 2010 | A1 |
| 20100094231 | Bleich et al. | Apr 2010 | A1 |
| 20100114087 | Edwards et al. | May 2010 | A1 |
| 20100116279 | Cooper | May 2010 | A9 |
| 20100125239 | Perry et al. | May 2010 | A1 |
| 20100130892 | Warnking | May 2010 | A1 |
| 20100137860 | Demarais et al. | Jun 2010 | A1 |
| 20100145427 | Gliner et al. | Jun 2010 | A1 |
| 20100152835 | Orr | Jun 2010 | A1 |
| 20100160906 | Jarrard | Jun 2010 | A1 |
| 20100160996 | Simon et al. | Jun 2010 | A1 |
| 20100174340 | Simon | Jul 2010 | A1 |
| 20100179424 | Warnking et al. | Jul 2010 | A1 |
| 20100185190 | Danek et al. | Jul 2010 | A1 |
| 20100191089 | Stebler et al. | Jul 2010 | A1 |
| 20100204689 | Danek et al. | Aug 2010 | A1 |
| 20100222851 | Deem et al. | Sep 2010 | A1 |
| 20100228318 | Errico et al. | Sep 2010 | A1 |
| 20100241188 | Errico et al. | Sep 2010 | A1 |
| 20100249873 | Errico | Sep 2010 | A1 |
| 20100256629 | Wylie et al. | Oct 2010 | A1 |
| 20100256630 | Hamilton et al. | Oct 2010 | A1 |
| 20100268222 | Danek et al. | Oct 2010 | A1 |
| 20100298905 | Simon | Nov 2010 | A1 |
| 20100305463 | Macklem et al. | Dec 2010 | A1 |
| 20100318020 | Atanasoska et al. | Dec 2010 | A1 |
| 20100331776 | Salahieh et al. | Dec 2010 | A1 |
| 20110004148 | Ishii | Jan 2011 | A1 |
| 20110015548 | Aldrich et al. | Jan 2011 | A1 |
| 20110028898 | Clark, III et al. | Feb 2011 | A1 |
| 20110046432 | Simon et al. | Feb 2011 | A1 |
| 20110060380 | Gelfand et al. | Mar 2011 | A1 |
| 20110079230 | Danek et al. | Apr 2011 | A1 |
| 20110093032 | Boggs, II et al. | Apr 2011 | A1 |
| 20110098762 | Rezai | Apr 2011 | A1 |
| 20110112400 | Emery et al. | May 2011 | A1 |
| 20110112521 | DeLonzor et al. | May 2011 | A1 |
| 20110118725 | Mayse et al. | May 2011 | A1 |
| 20110125203 | Simon et al. | May 2011 | A1 |
| 20110125213 | Simon et al. | May 2011 | A1 |
| 20110130708 | Perry et al. | Jun 2011 | A1 |
| 20110137284 | Arora et al. | Jun 2011 | A1 |
| 20110144630 | Loeb | Jun 2011 | A1 |
| 20110146673 | Keast et al. | Jun 2011 | A1 |
| 20110146674 | Roschak | Jun 2011 | A1 |
| 20110152855 | Mayse et al. | Jun 2011 | A1 |
| 20110152967 | Simon et al. | Jun 2011 | A1 |
| 20110152974 | Rezai et al. | Jun 2011 | A1 |
| 20110166499 | Demarais et al. | Jul 2011 | A1 |
| 20110166565 | Wizeman et al. | Jul 2011 | A1 |
| 20110172655 | Biggs et al. | Jul 2011 | A1 |
| 20110172658 | Gelbart et al. | Jul 2011 | A1 |
| 20110178569 | Parnis et al. | Jul 2011 | A1 |
| 20110184330 | Laufer et al. | Jul 2011 | A1 |
| 20110190569 | Simon et al. | Aug 2011 | A1 |
| 20110196288 | Kaplan et al. | Aug 2011 | A1 |
| 20110202098 | Demarais et al. | Aug 2011 | A1 |
| 20110224768 | Edwards | Sep 2011 | A1 |
| 20110230701 | Simon et al. | Sep 2011 | A1 |
| 20110230938 | Simon et al. | Sep 2011 | A1 |
| 20110245756 | Arora et al. | Oct 2011 | A1 |
| 20110251592 | Biggs et al. | Oct 2011 | A1 |
| 20110257622 | Salahieh et al. | Oct 2011 | A1 |
| 20110257647 | Mayse et al. | Oct 2011 | A1 |
| 20110263960 | Mitchell | Oct 2011 | A1 |
| 20110264086 | Ingle | Oct 2011 | A1 |
| 20110270249 | Utley et al. | Nov 2011 | A1 |
| 20110276107 | Simon et al. | Nov 2011 | A1 |
| 20110276112 | Simon et al. | Nov 2011 | A1 |
| 20110282229 | Danek et al. | Nov 2011 | A1 |
| 20110282418 | Saunders et al. | Nov 2011 | A1 |
| 20110301587 | Deem et al. | Dec 2011 | A1 |
| 20110301664 | Rezai | Dec 2011 | A1 |
| 20110301679 | Rezai et al. | Dec 2011 | A1 |
| 20110306851 | Wang | Dec 2011 | A1 |
| 20110306904 | Jacobson et al. | Dec 2011 | A1 |
| 20110306997 | Roschak et al. | Dec 2011 | A9 |
| 20110319958 | Simon et al. | Dec 2011 | A1 |
| 20120004656 | Jackson et al. | Jan 2012 | A1 |
| 20120015019 | Pacetti et al. | Jan 2012 | A1 |
| 20120016256 | Mabary et al. | Jan 2012 | A1 |
| 20120016358 | Mayse et al. | Jan 2012 | A1 |
| 20120016363 | Mayse et al. | Jan 2012 | A1 |
| 20120016364 | Mayse et al. | Jan 2012 | A1 |
| 20120029261 | Deem et al. | Feb 2012 | A1 |
| 20120029500 | Jenson | Feb 2012 | A1 |
| 20120029512 | Willard et al. | Feb 2012 | A1 |
| 20120029591 | Simon et al. | Feb 2012 | A1 |
| 20120029601 | Simon et al. | Feb 2012 | A1 |
| 20120041412 | Roth et al. | Feb 2012 | A1 |
| 20120041509 | Knudson et al. | Feb 2012 | A1 |
| 20120071870 | Salahieh et al. | Mar 2012 | A1 |
| 20120078096 | Krolik et al. | Mar 2012 | A1 |
| 20120083734 | Ayres et al. | Apr 2012 | A1 |
| 20120089078 | Deem et al. | Apr 2012 | A1 |
| 20120089138 | Edwards et al. | Apr 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120101413 | Beetel et al. | Apr 2012 | A1 |
| 20120109278 | Sih | May 2012 | A1 |
| 20120143132 | Orlowski | Jun 2012 | A1 |
| 20120143177 | Avitall | Jun 2012 | A1 |
| 20120143179 | Avitall | Jun 2012 | A1 |
| 20120143181 | Demarais et al. | Jun 2012 | A1 |
| 20120157986 | Stone et al. | Jun 2012 | A1 |
| 20120157987 | Steinke et al. | Jun 2012 | A1 |
| 20120157988 | Stone et al. | Jun 2012 | A1 |
| 20120157989 | Stone et al. | Jun 2012 | A1 |
| 20120158101 | Stone et al. | Jun 2012 | A1 |
| 20120165803 | Bencini et al. | Jun 2012 | A1 |
| 20120184801 | Simon et al. | Jul 2012 | A1 |
| 20120185020 | Simon et al. | Jul 2012 | A1 |
| 20120191081 | Markowitz | Jul 2012 | A1 |
| 20120191082 | Markowitz | Jul 2012 | A1 |
| 20120197100 | Razavi et al. | Aug 2012 | A1 |
| 20120197246 | Mauch | Aug 2012 | A1 |
| 20120197251 | Edwards et al. | Aug 2012 | A1 |
| 20120203067 | Higgins et al. | Aug 2012 | A1 |
| 20120203216 | Mayse et al. | Aug 2012 | A1 |
| 20120203222 | Mayse et al. | Aug 2012 | A1 |
| 20120209118 | Warnking | Aug 2012 | A1 |
| 20120209259 | Danek et al. | Aug 2012 | A1 |
| 20120209261 | Mayse et al. | Aug 2012 | A1 |
| 20120209296 | Mayse et al. | Aug 2012 | A1 |
| 20120221087 | Parnis et al. | Aug 2012 | A1 |
| 20120232436 | Warnking | Sep 2012 | A1 |
| 20120245415 | Emura et al. | Sep 2012 | A1 |
| 20120253442 | Gliner et al. | Oct 2012 | A1 |
| 20120259263 | Celermajer et al. | Oct 2012 | A1 |
| 20120259269 | Meyer | Oct 2012 | A1 |
| 20120259326 | Brannan et al. | Oct 2012 | A1 |
| 20120265280 | Errico et al. | Oct 2012 | A1 |
| 20120289952 | Utley et al. | Nov 2012 | A1 |
| 20120290035 | Levine et al. | Nov 2012 | A1 |
| 20120294424 | Chin et al. | Nov 2012 | A1 |
| 20120296329 | Ng | Nov 2012 | A1 |
| 20120302909 | Mayse et al. | Nov 2012 | A1 |
| 20120310233 | Dimmer et al. | Dec 2012 | A1 |
| 20120316552 | Mayse et al. | Dec 2012 | A1 |
| 20120316559 | Mayse et al. | Dec 2012 | A1 |
| 20120330298 | Ganz et al. | Dec 2012 | A1 |
| 20130012844 | Demarais et al. | Jan 2013 | A1 |
| 20130012866 | Deem et al. | Jan 2013 | A1 |
| 20130012867 | Demarais et al. | Jan 2013 | A1 |
| 20130035576 | O'Grady et al. | Feb 2013 | A1 |
| 20130123751 | Deem et al. | May 2013 | A1 |
| 20130289555 | Mayse et al. | Oct 2013 | A1 |
| 20130289556 | Mayse et al. | Oct 2013 | A1 |
| 20130296647 | Mayse et al. | Nov 2013 | A1 |
| 20130303948 | Deem et al. | Nov 2013 | A1 |
| 20130310822 | Mayse et al. | Nov 2013 | A1 |
| 20130345700 | Hlavka et al. | Dec 2013 | A1 |
| 20140186341 | Mayse | Jul 2014 | A1 |
| 20140236148 | Hlavka et al. | Aug 2014 | A1 |
| 20140257271 | Mayse et al. | Sep 2014 | A1 |
| 20140276792 | Kaveckis et al. | Sep 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 2419228 | Aug 2004 | CA |
| 101115448 | Jan 2008 | CN |
| 101115448 | May 2010 | CN |
| 19952505 | May 2001 | DE |
| 189329 | Jun 1987 | EP |
| 286145 | Oct 1988 | EP |
| 280225 | Mar 1989 | EP |
| 286145 | Oct 1990 | EP |
| 282225 | Jun 1992 | EP |
| 0 643 982 | Mar 1995 | EP |
| 908713 | Apr 1999 | EP |
| 1 143 864 | Oct 2001 | EP |
| 1 271 384 | Jan 2003 | EP |
| 1 281 366 | Feb 2003 | EP |
| 908150 | May 2003 | EP |
| 1 326 549 | Jul 2003 | EP |
| 768091 | Jul 2003 | EP |
| 1326548 | Jul 2003 | EP |
| 1 400 204 | Mar 2004 | EP |
| 1297795 | Aug 2005 | EP |
| 1 588 662 | Oct 2005 | EP |
| 2659240 | Jul 1997 | FR |
| 2233293 | Jan 1991 | GB |
| A 2000 271235 | Oct 2000 | JP |
| A 2002 503512 | Feb 2002 | JP |
| A 2002 541905 | Dec 2002 | JP |
| A 2003 510126 | Mar 2003 | JP |
| A 2011 519699 | Jul 2011 | JP |
| 2053814 | Feb 1996 | RU |
| 2091054 | Sep 1997 | RU |
| 8911311 | Nov 1989 | WO |
| 9301862 | Feb 1993 | WO |
| 9316632 | Sep 1993 | WO |
| 9407446 | Apr 1994 | WO |
| 9501075 | Jan 1995 | WO |
| 9502370 | Jan 1995 | WO |
| 9510322 | Apr 1995 | WO |
| 9604860 | Feb 1996 | WO |
| 9610961 | Apr 1996 | WO |
| 9725917 | Jul 1997 | WO |
| 9732532 | Sep 1997 | WO |
| 9733715 | Sep 1997 | WO |
| 9737715 | Oct 1997 | WO |
| 9740751 | Nov 1997 | WO |
| 9818391 | May 1998 | WO |
| 9844854 | Oct 1998 | WO |
| 9852480 | Nov 1998 | WO |
| 9856234 | Dec 1998 | WO |
| 9856324 | Dec 1998 | WO |
| 9903413 | Jan 1999 | WO |
| 9858681 | Mar 1999 | WO |
| 9913779 | Mar 1999 | WO |
| 9932040 | Jul 1999 | WO |
| 9942047 | Aug 1999 | WO |
| WO 9942044 | Aug 1999 | WO |
| 9964109 | Dec 1999 | WO |
| 0010598 | Mar 2000 | WO |
| 0051510 | Sep 2000 | WO |
| 0062699 | Oct 2000 | WO |
| WO 0062699 | Oct 2000 | WO |
| 0066017 | Nov 2000 | WO |
| 0100114 | Jan 2001 | WO |
| 0103642 | Jan 2001 | WO |
| WO 0122897 | Apr 2001 | WO |
| 0170114 | Sep 2001 | WO |
| 0189526 | Nov 2001 | WO |
| 0205720 | Jan 2002 | WO |
| 0205868 | Jan 2002 | WO |
| 0232333 | Apr 2002 | WO |
| 0232334 | Apr 2002 | WO |
| 03073358 | Sep 2003 | WO |
| 03088820 | Oct 2003 | WO |
| 2004078252 | Sep 2004 | WO |
| 2004082736 | Sep 2004 | WO |
| 2004101028 | Nov 2004 | WO |
| 2005006963 | Jan 2005 | WO |
| 2005006964 | Jan 2005 | WO |
| 2006053308 | May 2006 | WO |
| 2006053309 | May 2006 | WO |
| 2006116198 | Nov 2006 | WO |
| 2007058780 | May 2007 | WO |
| 2007061982 | May 2007 | WO |
| 2007092062 | Aug 2007 | WO |
| 2007094828 | Aug 2007 | WO |
| 2007143665 | Dec 2007 | WO |
| 2008005953 | Jan 2008 | WO |
| 2008024220 | Feb 2008 | WO |
| 2008051706 | May 2008 | WO |
| 2008063935 | May 2008 | WO |
| 2009009236 | Jan 2009 | WO |
| 2009015278 | Jan 2009 | WO |
| 2009082433 | Jul 2009 | WO |
| 2009126383 | Oct 2009 | WO |
| 2009137819 | Nov 2009 | WO |
| WO 2009137819 | Nov 2009 | WO |
| 2010110785 | Sep 2010 | WO |
| 2011060200 | May 2011 | WO |
| Entry |
|---|
| Abbott, “Present Concepts Relative to Autonomic Nerve Surgery in the Treatment of Pulmonary Disease,” American Journal of Surgery 90:479-489, 1955. |
| Ahnert-Hilger et al., “Introduction of Macromolecules into Bovine Adrenal-Medullary Chromaffin Cells and Rat Pheochromocytoma Cells (PC12) by Permeabilization with Streptolysin O: Inhibitory Effect of Tetanus Toxin on Catecholamine Secretion,” J. Neurochem 52(6):1751-1758, Jun. 1989. |
| Babichev et al., “Clinico-morphological comparisons in patients with bronchial asthma after denervation of the lungs,” Sov Med. 12:13-16, 1985. |
| Babichev et al., “Long-term results of surgical treatment of bronchial asthma based on adaptive response,” Khirurgiia (Mosk) 4:5-11, 1993. |
| Babichev et al., “Partial deneration of the lungs in bronchial asthma,” Khirurgiia (Mosk) 4:31-35, 1985. |
| Barlaw, “Surgical Treatment of Asthma,” Postgrad Med. Journal 25:193-196, 1949. |
| Bester et al., “Recovery of C-Fiber-Induced Extravasation Following Peripheral Nerve Injury in the Rat,” Experimental Neurology 154:628-636, 1998. |
| Bigalke et al., “Clostridial Neurotoxins,” Handbook of Experimental Pharmacology (Aktories, K., and Just, I., eds) 145:407-443, 2000. |
| Bittner et al., “Isolated Light Chains of Botulinum Neurotoxins Inhibit Exocytosis,” The Journal of Biological Chemistry 264(18):10354-10360, 1989. |
| Blindt et al., “Development of a New Biodegradable Intravascular Polymer Stent with Simultaneous Incorporation of Bioactive Substances,” The International Journal of Artificial Organs 22(12):843-853, 1999. |
| Bradley et al., “Effect of vagotomy on the breathing pattern and exercise ability in emphysematous patients,” Clinical Science 62:311-319, 1982. |
| Breekveldt-Postma et al., “Enhanced persistence with tiotropium compared with other respiratory drugs in COPD,” Respiratory Medicine 101:1398-1405, 2007. |
| Brody et al., “Mucociliary clearance after lung denervation and bronchial transection,” J. Applied Physiology 32(2):160-164, 1972. |
| Buzzi, “Diphtheria Toxin Treatment of Human Advanced Cancer,” Cancer Research 42:2054-2058, 1982. |
| Canning et al., “Reflex Mechanisms in Gastroesophageal Reflux Disease and Asthma,” The American Journal of Medicine 115(3A):45S-48S, 2003. |
| Canning et al., “Reflex Mechanisms in Gastroesophageal Reflux Disease and Asthma,” Am J Med. 115(Suppl 3A):45S-48S, 2003. (Abstract only.). |
| Canning, “Reflex regulation of airway smooth muscle tone,” J Appl. Physiol. (101):971-985, 2006. |
| Chaddock et al. “Expression and Purification of Catalytically Active, Non-Toxic Endopeptidase Derivatives of Clostridium botulinum Toxin Type A,” Protein Expression and Purification 25(2):219-228, Jul. 2002. |
| Chang, “Cell poration and cell fusion using an oscillating electric field,” Biophys. J. 56:641-652, 1989. |
| Chernyshova et al., “The Effect of Low-Energy Laser Radiation in the Infrared Spectrum on Bronchial Patency in Children With Bronchial Asthma,” Vopr Kurortol, Fizioter Lech Fiz Kult 2:11-14, 1995. |
| Chumakov et al., “Morphologic Studies of Bronchial Biopsies in Chronic Bronchitis Before and After Treatment,” Arkh. Patol. 57(6):21-25, 1995. (+ English abstract and translation, 8 pages). |
| Crimi et al., “Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine in asthma,” Eur Respir J 5:560-565, 1992. |
| Dimitrov-Szokodi et al., “Lung Denervation in the Therapy of Intractable Bronchial Asthma,” J. Thoracic Surg. 33(2):166-184, Feb. 1957. |
| Donohue et al., “A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol,” Chest 122:47-55, 2002. |
| De Paiva et al., “Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes,” FEBS Lett. 17:277(1-2): 171-174, Dec. 1990. |
| Feshenko et al., “Clinico-morphological comparisons in the laser therapy of chronic bronchitis patients,” Lik Sprava. (10-12):75-79, 1993. (+ English abstract, 1 Page.). |
| Friedman et al., “Healthcare Costs with Tiotropium Plus Usual Care versus Usual Care Alone Following 1 Year of Treatment in Patients with Chronic Obstructive Pulmonary Disorder (COPD),” Pharmacoeconomics 22(11):741-749, 2004. |
| Gelb et al., “Laser in treatment of lung cancer,” Chest 86(5):662-666, 1984. |
| George et al., “Factors Associated With Medication Nonadherence in Patients With COPD,” Chest 128:3198-3204, 2005. |
| Gerasin et al., “Endobronchial electrosurgery,” Chest 93:270-274, 1988. |
| Gibson et al., “Gastroesophageal Reflux Treatment for Asthma in Adults and Children,” Cochrane Database Syst. Rev. 2:CD001496, 2003. (Abstract only.). |
| Glanville et al., “Bronchial responsiveness after human heart-lung transplantation,” Chest 97(6):1360-1366, 1990. |
| Glanville et al., “Bronchial responsiveness to exercise after human cardiopulmonary transplantation,” Chest 96(2):81-286, 1989. |
| Gosens et al., “Muscarinic receptor signaling in the pathophysiology of asthma and COPD,” Respiratory Research 7(73):1-15, 2006. |
| Groeben et al. “High Thoracic Epidural Anesthesia Does Not Alter Airway Resistance and Attenuates the Response to an Inhalational Provocation Test in Patients with Bronchial Hyperreactivity,” Anesthesiology 81(4):868-874, 1994. |
| Guarini et al., “Efferent Vagal Fibre Stimulation Blunts Nuclear Factor-kB Activation and Protects Against Hypovolemic Hemmorrhagic Shock,” Circulation 107:1189-1194, 2003. |
| Guzmán et al., “Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius,” Ultrasound in Med. & Biol. 29(8):1211-1222, 2003. |
| Hainsworth et al., “Afferent lung denervation by brief inhalation of steam,” Journal of Applied Physiology (34)5: 708-714, 1972. |
| Harding, “Recent Clinical Investigations Examining the Association of Asthma and Gastroesophageal Reflux,” Am J Med. 115(Suppl 3A):39S-44S, 2003. (Abstract only.). |
| Hiraga, “Experimental surgical therapy of bronchial asthma. The effect of denervation in dogs,” Nihon Kyobu Shikkan Gakkai Zasshi 19(1):46-56, 1981. |
| Hoffmann et al., “Inhibition of Histamine-Induced Bronchoconstriction in Guinea Pig and Swine by Pulsed Electrical Vagus Nerve Stimulation,” Neuromodulation: Technology at the Neural Interface:1-9, 2009. |
| Hooper et al., “Endobronchial electrocautery,” Chest 87(6):12-714, 1985. |
| Ivanyuta Om, et al., “Effect of Low-Power Laser Irradiation of Bronchia Mucosa on the State of Systemic and Local Immunity in Patients with Chronic Bronchitis,” Problemy Tuberkuleza 6:26-29, 1991. |
| Jammes et al., “Assessment of the Pulmonary Origin of Bronchoconstrictor Vagal Tone,” J. Physiol. 291: 305-316, 1979. |
| Jiang et al., “Effects of Antireflux Treatment on Bronchial Hyper-responsiveness and Lung Function in Asthmatic Patients with Gastroesophageal Reflux Disease,” World J Gastroenterol. 9:1123-1125, 2003. (Abstract only.). |
| Karashurov et al., “Electrostimulation in the therapy of bronchial asthma,” Klin Med (Mosk)79(1):38-41, 2001. |
| Karashurov et al., “Radiofrequency electrostimulation of carotid sinus nerves for the treatment of bronchial asthma,” Khirurgiia (Mosk) 12:2-6, 1999. |
| Khmel'kova et al., “Does laser irridation affect bronchial obstruction?,” Probl Tuberk 3:41-42, 1995. (Abstract only.). |
| Khoshoo et al., “Role of Gastroesophageal Reflux in Older Children with Persistent Asthma,” Chest 123:1008-1013, 2003. (Abstract only.). |
| Kiljander, “The Role of Proton Pump Inhibitors in the Management of Gastroesophageal Reflux Disease-Related Asthma and Chronic Cough,” Am J Med. 115(Suppl 3A):65S-71S, 2003. (Abstract only.). |
| Kistner et al., “Reductive Cleavage of Tetanus Toxin and Botulinum Neurotoxin A by the Thioredoxin System from Brain,” Naunyn-Schmiedebergs Arch Pharmacol 345(2):227-234, Feb. 1992. |
| Kletskin et al., “Value of assessing the autonomic nervous system in bronchial asthma in selecting the surgical treatment method,” Khirurgiia (Mosk) 7:91-95, 1987. |
| Kliachkin et al., “Bronchoscopy in the treatment of bronchial asthma of infectious allergic origin,” Ter Arkh 54(4):76-79, 1982. |
| Korochkin et al., “Use of a Helium-Neon Laser in Combined Treatment of Bronchial Asthma,” New Developments in Diagnostics and Treatment, 1990, 9 pgs. |
| Korpela et al., “Comparison of Tissue Reactions in the Tracheal Mucosa Surrounding a Bioabsorbable and Silicone Airway Stents,” Annals of Thoracic Surgery 66:1772-1776, 1998. |
| Kozaki et al., “New surgical treatment of bronchial asthma—denervation of the hilus pulmonis (2),” Nippon Kyobu Geka Gakkai Zasshi 22(5):465-466, 1974. |
| Kreitman, “Taming ricin toxin,” Nature Biotechnology 21:372-374, 2003. |
| Kuntz, “The Autonomic Nervous System in Relation to the Thoracic Viscera,” Chest 10:118, 1944. |
| Lennerz et al., “Electrophysiological characterization of vagal afferents relevant to mucosal nociception in the rat upper oesophagus,” J. Physiol. 582(1):229-242, 2007. |
| Levin, “The Treatment of Bronchial Asthma by Dorsal Sympathectomy,” Annals of Surgery 102(2):161-170, 1935. |
| Liou et al., “Causative and Contributive Factors to Asthmas Severity and Patterns of Medication Use in Patients Seeking Specialized Asthma Care,” Chest 124:1781-1788, 2003. (Abstract only.). |
| Løkke et al., “Developing COPD: a 25 year follow up study of the general population,” Thorax 61:935-939, 2006. |
| Maesen et al., “Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD),” Eur. Respi. J. 8:1506-1513, 1995. |
| Magnussen et al., “Effect of Inhaled Ipratropium Bromide on the Airway Response to Methacholine, Histamine, and Exercise in Patients with Mild Bronchial Asthma,” Respiration 59:42-47, 1992. |
| Maltais et al., “Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD,” Chest 128:1168-1178, 2005. |
| Mathew et al., “Gastro-oesophageal reflux and bronchial asthma: current status and future directions,” Postgrad Med. J. 80:701-705, 2004. |
| McKay et al., “Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle,” Respir Res 3(11):1-13, 2002. |
| Mehta et al., “Effect of endobronchial radiation therapy on malignant bronchial obstruction,” Chest 97(3):662-665, 1990. |
| Meshalkin et al., “Partial denervation of the pulmonary hilus as one of the methods of surgical treatment of bronchial asthma,” Grudn Khir 1:109-111, 1975. |
| Moore, Keith L., Clinically Oriented Anatomy, 2nd ed., Williams & Wilkins, Baltimore, 1985, pp. 85 and 87. (Abstract only.). |
| Netter, Frank H., The Ciba Collection of Medical Illustrations: vol. 7, Respiratory System, CIBA-GEIGY Corporation, West Caldwell, 1979, p. 23, section 1. (Abstract only.). |
| Ochs, Matthias et al., Fisherman, Alfred P., et al. (eds), Functional Design of the Human Lung for Gas Exchange, 4th ed., McGraw Hill Medical, New York, 2008, Chap. 2, “Fisherman's Pulmonary Diseases and Disorders.” (Abstract only.). |
| O'Connor et al., “Prolonged Effect of Tiotropium Bromide on Methacholine-induced Bronchoconstriction in Asthma,” Am. J. Respir. Crit. Care Med. 154:876-880, 1996. |
| Ovcharenko et al., “Endobronchial use of low-frequency ultrasound and ultraviolet laser radiation in the complex treatment of patients with suppurative bronchial diseases,” Probl Tuberk 3:40-42, 1997. (Abstract only.). |
| Overholt, “Glomectomy for Asthma,” Dis Chest 40:605-610, 1961. |
| Peters et al., “Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma,” New England Journal of Medicine 363(18):1715-1726, Oct. 28, 2010. |
| Petrou, et al., “Bronchoscopic Diathermy Resection and Stent Insertion: a Cost Effective Treatment for Tracheobronchial Obstruction,” Thorax 48:1156-1159, 1993. |
| Polosukhin, “Dynamics of the ultrastructural changes in blood and lymphatic capillaries of bronchi in inflammation and following endobronchial laser therapy,” Virchows Arch. 431:283-290, 1997. |
| Polosukhin, “Regeneration of Bronchial Epithelium on Chronic Inflammatory Changes Under Laser Treatment,” Path. Res. Pract. 192:909-918, 1996. |
| Polosukhin, “Ultrastructural study of the destructive and repair processes in pulmonary inflammation and following endobronchial laser therapy,” Virchows Arch. 435:13-19, 1999. |
| Polosukhin, “Ultrastructure of the Blood and Lymphatic Capillaries of the Respiratory Tissue During Inflammation and Endobronchial Laser Therapy,” Ultrastructural Pathology 24:183-189, 2000. |
| Provotorov VM, et al., “Clinical Efficacy of Treatment of Patients with Non-Specific Pulmonary Diseases by Using Low-Power Laser Irradiation and Performing Intrapulmonary Drug Administration,” Terapevichesky Arkhiv 62:18-23, 1991. |
| Raj, “Editorial,” Pain Practice 4(1S): Sl-S3, 2004. |
| Ramirez et al., “Sympathetomy in Bronchial Asthma,” J. A. M. A. 84 (26):2002-2003, 1925. |
| Rienhoff et al., “Treatment of Intractable Bronchial Asthma by Bilateral Resection of the Posterior Pulmonary Plexus,” Arch Surg 37(3):456-469, 1938. |
| Savchenko et al., “Adaptation of regulatory physiological systems in surgical treatment of patients with bronchial asthma,” Klin Med (Mosk) 74(7):38-39, 1996. |
| Sengupta, “Part 1 Oral cavity, pharynx and esophagus—Esophageal sensory physiology,”, GI Motility online:17 pages, 2006. |
| Sepulveda et al., “Treatment of Asthmatic Bronchoconstriction by Percutaneous Low Voltage Vagal Nerve Stimulation: Case Report,” Internet Journal of Asthma, Allergy, and Immunology 7(2):3 pages, 2009. |
| Shaari et al., “Rhinorrhea is Decreased in Dogs After Nasal Application of Botulinum Toxin,” Otolaryngol Head Neck Surg 112(14):566-571, 1992. |
| Sheski FD, et al., “Cryotherapy, Electrocautery, and Brachytherapy,” Clinics in Chest Medicine 20(1):123-138, Mar. 1999. |
| Sil'vestrov et al., “The Clinico-Pathogenetic Validation and Efficacy of the Use of Low-Energy Laser Irradiation and Glucocorticoids in the Treatment of Bronchial Asthma Patients,” Ter Arkh 63(11), 87-92, 1991. |
| Simonsson et al., “Role of Autonomic Nervous System and the Cough Reflex in the Increased Responsiveness of Airways in Patients with Obstructive Airway Disease,” The Journal of Clinical Investigation 46(11): 1812-1818, 1967. |
| Simpson et al., “Isolation and Characterization of the Botulinum Neurotoxins,” Methods Enzymol 165:76-85, 1988. |
| Smakov, “Denervation of the lung in the treatment of bronchial asthma,” Khirurgiia (Mosk) 9:117-120, 1982. |
| Smakov, “Pathogenetic substantiation of lung denervation in bronchial asthma and it's indications,” Khirurgiia (Mosk) 2:67-69, 1999. |
| Smakov, “Prognostication of the effect of therapeutic bronchoscopy in patients with bronchial asthma according to the state of local immunity,” Klin Med (Mask) 73(5):76-77, 1995. |
| Sontag et al., “Asthmatics with Gastroesophageal Reflux: Long-term Results of a Randomized Trial of Medical and Surgical Antireflux Therapies,” Am J Gastroenterol. 98:987-999, 2003. (Abstract only.). |
| Stein, “Possible Mechanisms of Influence of Esophageal Acid on Airway Hyperresponsiveness,” Am J Med. 115(Suppl 3A):55S-59S, 2003. (Abstract only.). |
| Sundaram et al., “An Experimental and Theoretical Analysis of Ultrasound-Induced Permeabilization of Cell Membranes,” Biophysical Journal 84:3087-3101, 2003. |
| Takino et al., “Surgical Removal of the Carotid Body and its Relation to the Carotid Chemoreceptor and Baroreceptor Reflex in Asthmatics,” Dis Chest 47:129-138, 1965. |
| Tashkin et al., “Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses,” Chest 123: 1441-1449, 2003. |
| Tsugeno et al., “A Proton-Pump Inhibitor, Rabeprazole, Improves Ventilatory Function in Patients with Asthma Associated with Gastroesophageal Reflux,” Scand J Gastroenterol. 38:456-461, 2003. (Abstract only.). |
| Tsuji et al., “Biodegradable Stents as a Platform to Drug Loading,” International Journal of Cardiovascular Interventions 5:13-16, 2003. |
| Unal et al., “Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial,” Acta Oto-Laryngologica 123(9):1060-0163, Dec. 2003. |
| Van Boxem JTM, et al., “Tissue Effects of Bronchoscopic Electrocautery,” Chest 117(3):887-891, Mar. 1999. |
| van der Velden et al., “Autonomic Innervation of Human Airways: Structure, Function, and Pathophysiology in Asthma,” Neuroimmunomodulation 6:145-159, 1999. |
| Verhein et al., “Neural Control of Airway Inflammation,” Current Allergy and Asthma Reports 9:484-490, 2009. |
| Vincken et al., “Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium,” Eur. Respir. J. 19: 209-216, 2002. |
| Vorotnev et al., “Treatment of Patients with Chronic Obstructive Bronchitis Using Low Energy Laser at a General Rehabilitation Center,” Therapeutic Archive 3:17-19, 1997. (+English translation, 4 pages). |
| Wagner et al., “Methacholine causes reflex bronchoconstriction,” J. Appl. Physiol. 86:294-297, 1999. |
| Wahidi et al., “State of the Art: Interventional Pulmonology,” Chest 131:261-274, 2007. |
| Weaver, “Electroporation: A General Phenomenon for Manipulating Cells and Tissues,” Journal of Cellular Biochemistry 51(4):426-435, Apr. 1993. |
| Wirtz et al., “Bilateral Lung Transplantation for Severe Persistent and Difficult Asthma,” The Journal of Heart and Lung Transplantation 24(10):1700-1703, 2005. |
| Laufer, “Method and Apparatus for Treating Smooth Muscles in the Walls of Body Conduits,” U.S. Appl. No. 09/095,323, filed Jun. 10, 1998, 25 pages. |
| Global Strategy for Asthma Management and Prevention, 2002, 192 Pages Total. |
| James, et al., “The Mechanics of Airway Narrowing in Asthma,” Am. Rev. Respir. Dis., 1989, 139, 242-246. |
| Janssen L. J., “Asthma therapy: how far have we come, why did we fail and where should we go next?,” Eur Respir J, 2009, 33, pp. 11-20. |
| Kitamura S., “Color Atlas of Clinical Application of Fiberoptic Bronchoscopy,” 1990, Year Book Medical Publishers, 17. |
| Kraft M., “The distal airways: are they Important in asthma?,” European Respiratory, 1999, 1403-1417. |
| Notice of final Rejection, Japanese Patent Application No. 2000-553172, dated Sep. 2, 2008, 5 pages. |
| PCT International search report for application No. PCT/US00/05412 mailed on Jun. 20, 2000, 2 pages. |
| PCT International search report for application No. PCT/US00/18197 mailed on Oct. 3, 2000, 1 page. |
| PCT International search report for application No. PCT/US00/28745 mailed on Mar. 28, 2001, 6 pages. |
| PCT International search report for application No. PCT/US01/32321 mailed on Jan. 18, 2002, 2 pages. |
| PCT International search report for application No. PCT/US98/03759 mailed on Jul. 30, 1998, 1 page. |
| PCT International search report for application No. PCT/US98/26227 mailed on Mar. 25, 1999, 1 page. |
| PCT International search report for application No. PCT/US99/00232 mailed on Mar. 4, 1999, 1 page. |
| PCT International search report for application No. PCT/US99/12986 mailed on Sep. 29, 1999, 1 page. |
| Peter K. Jeffery, “Remodeling in Asthma and Chronic Obstructive Lung Disease,” American Journal of Respiratory and Critical Care Medicine, 2001, 164 (10), 13516. |
| Seow C. Y., et al. “Signal Transduction in Smooth Muscle Historical perspective on airway smooth muscle: the saga of a frustrated cell,” J Appl Physiol, 2001, 91, 938-952. |
| Stephanie A.Shore, “Airway Smooth Muscle in Asthma—Not Just More of the Same.” N. Engl J Med, 2004, 351 (6), 531-532. |
| Wayne Mitzner, “Airway Smooth Muscle the appendix of the Lung,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, 787-790. |
| Wayne Mitzner, “Bronchial Thermoplasty in Asthma,” Allergology International, 2006, 55, 225-234. |
| Non-Final Office Action for U.S. Appl. No. 11/398,353; Mailed on Aug. 31, 2009; 7 pages. |
| Non-Final Office Action for U.S. Appl. No. 11/398,353; Mailed on Apr. 27, 2010; 8 pages. |
| Co-pending U.S. Appl. No. 09/244,173. |
| Co-pending U.S. Appl. No. 09/095,323. |
| Simon R. Johnson et al., Synthetic Functions of Airway Smooth Muscle in Asthma, Trends Pharmacol. Sci., Aug. 1997, 18(8), 288-292. |
| MacKlem P.T., Mechanical Factors Determining Maximum Bronchoconstriction, European Respiratory Journal, Jun. 1989, 6, 516s-519s. |
| James C. Hogg, The Pathology of Asthma, APMIS, Oct. 1997, 105(10), 735-745. |
| Dierkesmann et al., Indication and Results of Endobronchial Laser Therapy, Lung, 1990, 168, 1095-1102. |
| Netter F.H., Respiratory System: A Compilation of Paintings Depicting Anatomy and Embryology, Physiology, Pathology, Pathophysiology, and Clinical Features and Treatment of Diseases, in the CIBA Collection of Medical Illustrations M.B. Divertie, ed., Summit New Jersey, 1979, vol. 7, 119-135. |
| Provotorov et al.; The Clinical Efficacy of Treating Patients with Nonspecific Lung Disease by Using Low-energy Laser Irradiation and Intrapulmonary Drug Administration, ISSN: 00403660., Terapevticheskii Arkhiv (USSR), 1991, 63 (12), 18-23. |
| Wiggs B.R. et al., On the Mechanism of Mucosal Folding in Normal and Asthmatic Airways, J. Appl. Physiol., Dec. 1997, 83(6), 1814-1821. |
| An, S. S. et al., Airway smooth muscle dynamics; a common pathway of airway obstruction in asthma, European Respiratory Journal, 2007, vol. 29, No. 5, pp. 834-860. |
| Bel, E, H., Hot Stuff: Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, vol. 173, pp. 941-942. |
| Brown, R. H. et al., In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography. Journal of Applied Physiology, 2005, vol. 98, pp. 1603-1606. |
| Chhajed, P., Will There be a Role for Bronchoscopic Radiofrequency Ablation?, 2005, J Bronchol, vol. 12, No. 3, p. 184. |
| Cox, G., et al, . Early Clinical Experience With Bronchial Thermoplasty for the Treatment of Asthma, 2002, p. 1068. |
| Cox, G. et al., Asthma Control During the Year After Bronchial Thermoplasty, The New England Journal of Medicine, Mar. 29, 2007, vol. 356, No. 13, pp. 1327-1337. |
| Cox. G. et al., Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting, 2004, p. 1. |
| Cox, G., et al., Development of a Novel Bronchoscope Therapy for Asthma, Journal of Allergy and Clinical Immunology, 2003, p. 1. |
| Cox, G., et al., Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, vol. 173, pp. 965-969. |
| Cox, G., et al., Bronchial Thermoplasty: Long-Term Follow-up and Patient Satisfaction, 2004, p. 1. |
| Cox, G., et al., Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations, European Respiratory Journal, 2004, 24, pp. 659-663. |
| Cox, G., et al., Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma, 2003, Chest 124, p. 106S. |
| Cox, G., et al., Impact of bronchial thermoplasty on asthma status: interim results from the AIR trial, 2006, European Respiratory Society Annual. Meeting, Munich, Germany, p. 1. |
| Danek, C. J., et al., Bronchial thermoplasty reduces canine airway responsiveness to local methacholine challenge, 2002, American Thoracic Society Annual Meeting, p. 1. |
| Danek, C. J., et al., Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty™; Early Results, 2002, American Thoracic Society Annual Meeting, p. 1. |
| Danek, C. J., et al., Reduction in airway hyperesponsiveness to methacholine by the application of RF energy in dogs, J Appl Physiol, 2004, vol. 97, pp. 1946-1933. |
| Solway, J. et al., Airway Smooth Muscle as a Target for Asthma Therapy, the New England Journal of Medicine, Mar. 29, 2007, 356(13), pp. 1367-1369. |
| Lavioletts, et al. Asthma Intervention Research (AIR) Trial: Early Safety Assessment of Bronchial Thermoplasty, 2004, p. 1. |
| Leff et al., Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Dogs; a Possible Procedure for the Treatment of Asthma, American Thoracic Society Annual Meeting, 2002, p. 1. |
| Lim, E.E. et al., Botulinum Toxin: A Novel Therapeutic Option for Bronchial Asthma?, Medical Hypotheses, 2006, vol. 66, pp. 915-919. |
| Lombard, et al, Histologic Effects of Bronchial Thermoplasty of Canine and Human Airways, American Thoracic Society Annual Meeting, 2002, p. 1. |
| Mayse, M. et al., Clinical Pearls for Bronchial Thermoplasty, J Bronchol, Apr. 2007, vol. 14, No. 2, pp. 115-123. |
| Miller. J. D. et al., A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway. 2005. vol. 127, No. 6 pp. 1999-2006. |
| Miller, J. D. et al., Bronchial Thermoplasty is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy, 2002, American Thoracic Society Annual Meeting, p. 1. |
| Rubin, et al., Bronchial Thermoplasty improves Asthma Status of Moderate to Severe Persistent Asthmatics Over and Above Current Standard-of-Care, 2006, American College of Chest Physicians, 2 pages. |
| Sterk, P. J., Heterogeneity of Airway Hyperresponsiveness: Time for Unconventional, but Traditional Studies, 2004, The American Pshychoiogical Society, pp. 2017-2018. |
| Wilson, S. R. et al., Global assessment after bronchial thermoplasty: the patient's perspective, Journal of Outcomes Research, 2006, vol. 10, pp. 37-46. |
| Toma, T. P., Brave New World for Interventional Bronchoscopy, 2005, Thorax, vol. 60, pp. 180-181. |
| Trow, T., Clinical Year in Review I, proceedings of the American Thoracic Society, 2006, vol. 3, pp. 553-556. |
| Wizeman, et al., A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery, 2007, American Thoracic Society Annual Meeting, p. 1. |
| Shesterina. M. V. et al., Effect of laser therapy on immunity in patients with bronchial asthma and pulmonary tuberculosis, 1993, pp. 23-26. |
| Evis Exera Bronchovideoscope Brochure, Olympus BF-XT160, Olympus, Jun. 15, 2007, 2 pages. |
| Accad, M., “Single-Step Renal Denervation With the OneShot™ Ablation System,” presentation at the Leipzig Interventional Course 2012 in Leipzig, Germany, Jan. 26, 2012, 11 pages. |
| Bertog, S., “Covidien-Maya: OneShot™,” presentation at the 2012 Congenital & Structural Interventions Congress in Frankfurt, Germany, Jun. 28, 2012, 25 pages. |
| Rocha-Singh, K.J., “Renal Artery Denervation: A Brave New Frontier,” Endovascular Today, Feb. 2012, pp. 45-53. |
| Gaude, G.S., “Pulmonary Manifestations of Gastroesophageal Reflux Disease,” Annals of Thoracic Medicine 4(3):115-123, Jul.-Sep. 2009. |
| Awadh, N., et al. “Airway Wall Thickness in Patients With Near Fatal Asthma and Control Groups: Assessment With High Resolution Computed Tomographic Scanning,” Thorax 53:248253, 1998. |
| Castro, M., et al., “Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial,” American Journal of Respiratory and Critical Care Medicine 181: 116-124, 2010. |
| Martin, N., et al., “Bronchial Thermoplasty for the Treatment of Asthma,” Current Allergy and Asthma Reports 9(1):88-95, Jan. 2009. |
| McEvoy, C.E., et al., “Changing the Landscape: Bronchial Thermoplasty Offers a Novel Approach to Asthma Treatment,” Advance for Managers of Respiratory Care, pp. 22, 24-25, Oct. 2007. |
| Michaud, G., et al., “Positioned for Success: Interest in Diagnostic and Therapeutic Bronchoscopy is Growing,” Advance for Managers of Respiratory Care, pp. 40, 42-43, Jul./Aug. 2008. |
| O'Sullivan, M.P., et al., “Apoptosis in the Airways: Another Balancing Act in the Epithelial Program,” American Journal of Respiratory Cell and Molecular Biology 29:3-7, 2003. |
| Pavord, I.D., et al., “Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma,” American Journal of Respiratory and Critical Care Medicine 176:1185-1191, 2007. |
| Tschumperlin, D.J., et al., “Chronic Effects of Mechanical Force on Airways,” Annual Review of Physiology 68: 563-83, 2006. |
| Tschumperlin, D.J., et al., “Mechanical Stimuli to Airway Remodeling,” American Journal of Respiratory and Critical Care Medicine 164:S90-S94, 2001. |
| Wechsler, M.E., “Bronchial Thermoplasty for Asthma: A Critical Review of a New Therapy,”, Allergy and Asthma Proceedings 29(4):1-6, Jul.-Aug. 2008. |
| Co-Pending U.S. Appl. No. 13/523,223, filed Jun. 14, 2012, Edwin J. Hlavka et al. |
| Preliminary Amendment and Response to Restriction Requirement filed Oct. 22, 2012, in co-pending U.S. Appl. No. 13/523,223, filed Jun. 14, 2012, Edwin J. Hlavka et al. |
| Co-Pending U.S. Appl. No. 12/372,607, filed Feb. 17, 2009, Edwin J. Hlavka et al. |
| Amendment After Allowance filed Sep. 17, 2012, in co-pending U.S. Appl. No. 12/372,607, filed Feb. 17, 2009, Edwin J. Hlavka et al. |
| Montaudon, M., et al., “Assessment of bronchial wall thickness and lumen diameter in human adults using multi-detector computed tomography: comparison with theoretical models,” J. Anat. 211:579-588, 2007. |
| Urologix, Inc., “CTC Advance™ Instructions for Use,” Targis® System Manual, 2010, 8 pages. |
| Brown, R.H. et al., Effect of bronchial thermoplasty on airway distensibility, European Respiratory Journal, vol. 26, No. 2, pp. 277-282; Aug. 2005. |
| Printout of “Cooled ThermoTherapy™,” Urologix, Inc., <http://www.urologix.com/clinicians/cooled-thermotherapy.php, 2 pages; printout dated Mar. 3, 2005. |
| Vasilotta, P.I. et al., “I-R Laser: A new Therapy in Rhino-Sino-Nasal Bronchial Syndrome with Asthmatic Component,” American Society for Laser medicine and Surgery abstracts; 1 page, facsimile copy dated Feb. 8, 2007. |
| Wilson, K.C., et al., “Flexible Bronchoscopy: Indications and Contraindications,” UpToDate (Ed, Rose, B) www.uptodate.com; 15 pages; Oct. 2010. |
| Office Action from Application JP 2011508719, dated Aug. 6, 2013, 7 pgs. |
| Extended European Search Report from Application EP 13003665.0, dated Oct. 16, 2013, 6 pgs. |
| Extended European Search Report from Application EP 13003667.6, dated Oct. 16, 2013, 7 pgs. |
| Extended European Search Report from Application EP 13003666.8, dated Oct. 16, 2013, 7 pgs. |
| Office Action from Application EP 12005299.8, dated Oct. 31, 2013, 4 pgs. |
| Office Action from Application CN 200980116717, dated Nov. 11, 2013, 5 pgs. |
| Secondary Office Action from Application JP 2011508719, dated Mar. 4, 2014, 5pgs. |
| Office Action from Application AU 2009244058, dated May 1, 2014, 4 pgs. |
| Summons to Attend Oral Proceedings from Application EP 09743805.5, dated Jul. 14, 2014, 5 pgs. |
| Office Action from Application EP 12005299.8, dated Aug. 4, 2014, 5 pgs. |
| Final Office Action from Application JP 2011508719, dated Oct. 30, 2014, 8 pgs. |
| Application and File History for U.S. Appl. No. 12/913,702, filed Oct. 27, 2010, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/245,529, filed Sep. 26, 2011, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/245,537, filed Sep. 26, 2011, U.S. Pat. No. 8,932,289, issued Jan. 13, 2015, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/931,208, filed Jun. 28, 2013, U.S. Pat. No. 8,777,943, issued Jul. 15, 2014, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/930,825, filed Jun. 28, 2013, U.S. Pat. No. 8,740,895, issued Jun. 3, 2014, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/931,246, filed Jun. 28, 2013, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/509,581, filed Aug. 14, 2012, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 12/463,304, filed May 8, 2009, U.S. Pat. No. 8,088,127, issued on Jan. 3, 2012, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/168,893, filed Jun. 24, 2011, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/245,522, filed Sep. 26, 2011, U.S. Pat. No. 8,226,638, issued Jul. 24, 2012, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/452,660, filed Apr. 20, 2012, U.S. Pat. No. 8,821,489, issued Sep. 2, 2014, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/452,664, filed Apr. 20, 2012, U.S. Pat. No. 8,808,280, issued Aug. 19, 2014, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/584,142, filed Aug. 13, 2012, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/452,648, filed Apr. 20, 2012, inventors Mayse et al. |
| Application and File History for U.S. Appl. No. 13/452,655, filed Apr. 20, 2012, inventors Mayse et al. |
| Communication dated May 20, 2016 for EP Application No. 13003666.8, 5 pages. |
| Communication dated May 20, 2016 for EP Application No. 13003665.0, 4 pages. |
| Search Report dated Aug. 27, 2015 for EP Application No. 13003665.0, 4 pages. |
| Search Report dated Aug. 27, 2015 for EP Application No. 13003667.6, 4 pages. |
| Search Report dated Aug. 27, 2015 for EP Application No. 13003666.8, 4 pages. |
| Office Action dated Aug. 10, 2015 for Canadian Application No. 2,723,806, 4 pages. |
| Office Action dated Sep. 16, 2015 for KR Application No. 1020107026952, 17 pages. |
| Office Action dated Jan. 5, 2016 for JP Application No. 2015-014893, 11 pages. |
| Office Action dated Sep. 20, 2016 for Canadian Application No. 2,723,806, 5 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20120316559 A1 | Dec 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61155449 | Feb 2009 | US | |
| 61106490 | Oct 2008 | US | |
| 61052082 | May 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13452664 | Apr 2012 | US |
| Child | 13592075 | US | |
| Parent | 13245522 | Sep 2011 | US |
| Child | 13452664 | US | |
| Parent | 12463304 | May 2009 | US |
| Child | 13245522 | US |
